TOXICOLOGICAL PROFILE FOR 

HMX 

Prepared by:
 

Sciences International, Inc.
 

Under Subcontract to:
 

Research Triangle Institute
 

Under Contract No. 205934606
 

Prepared for:
 

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Public Health Service
 

Agency for Toxic Substances and Disease Registry
 

September 1997 
HMX ii 

DISCLAIMER 

The use of company or product name(s) is for identification only and does not imply endorsement by 

the Agency for Toxic Substances and Disease Registry. 
HMX iii 

UPDATE STATEMENT 

Toxicological profiles are revised and republished as necessary, but no less than once every three 

years. For information regarding the update status of previously released profiles, contact ATSDR at: 

Agency for Toxic Substances and Disease Registry
 

Division of Toxicology/Toxicology Information Branch
 

1600 Clifton Road NE, E-29
 

Atlanta, Georgia 30333
 


HMX vi 

*Legislative Background 

The toxicological profiles are developed in response to the Superfund Amendments and 

Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 

Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). Section 

211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental 

Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense 

to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found 

unregulated hazardous substances at defense facilities. Section 2704(b) of Title 10 of the U. S. Code 

directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to 

prepare a toxicological profile for each substance on the list provided by the Secretary of Defense 

under subsection (b). 
HMX vii 

CONTRIBUTORS 

CHEMICAL MANAGER(S)/AUTHOR(S): 

Henry Abadin, MSPH
 

ATSDR, Division of Toxicology, Atlanta, GA
 

John J. Liccione, Ph.D.
 

Sciences International, Inc., Alexandria, VA
 

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
 

1. Green Border Review. Green Border review assures the consistency with ATSDR policy. 

2. Health Effects Review. The Health Effects Review Committee examines the health effects 

chapter of each profile for consistency and accuracy in interpreting health effects and 

classifying end points. 

3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 

substance-specific minimal risk levels (MRLs), reviews the health effects database of each 

profile, and makes recommendations for derivation of MRLs. 

HMX ix 

PEER REVIEW 

A peer review panel was assembled for HMX. The panel consisted of the following members: 

1. Dr. Tim Borges, Technical Information Analyst, Clinton, Tennessee 

2. Mr. Bruce Jacobs, Director, General Physics Corporation, Edgewood, Maryland 

3. Dr. Ronald Spanggord, Director of Bio-Analytical Chemistry, SRI International, Menlo Park, 

California 

These experts collectively have knowledge of HMX’s physical and chemical properties, toxicokinetics, 

key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 

humans. All reviewers were selected in conformity with the conditions for peer review specified in 

Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, 

as amended. 

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the 

peer reviewers’ comments and determined which comments will be included in the profile. A listing 

of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of the 

rationale for their exclusion, exists as part of the administrative record for this compound. A list of 

databases reviewed and a list of unpublished documents cited are also included in the administrative 

record. 

The citation of the peer review panel should not be understood to imply its approval of the profile’s 

final content. The responsibility for the content of this profile lies with the ATSDR. 









HMX 1 

1. PUBLIC HEALTH STATEMENT
 

This Statement was prepared to give you information about HMX and to emphasize the human health 

effects that may result from exposure to it. The Environmental Protection Agency (EPA) has 

identified 1,416 hazardous waste sites as the most serious in the nation. These sites make up the 

National Priorities List (NPL) and are the sites targeted for long-term federal cleanup activities. HMX 

has been found in at least 10 of the sites on the NPL. However, the number of NPL sites evaluated 

for HMX is not known. As EPA evaluates more sites, the number of sites at which HMX is found 

may increase. This information is important because exposure to HMX may cause harmful health 

effects and because these sites are potential or actual sources of human exposure to HMX. 

When a substance is released from a large area, such as an industrial plant, or from a container, such 

as a drum or bottle, it enters the environment. This release does not always lead to exposure. You 

can be exposed to a substance only when you come in contact with it. You may be exposed by 

breathing, eating, or drinking substances containing the substance or by skin contact with it. 

If you are exposed to a substance such as HMX, many factors will determine whether harmful health 

effects will occur and what the type and severity of those health effects will be. These factors include 

the dose (how much), the duration (how long), the route or pathway by which you are exposed 

(breathing, eating, drinking, or skin contact), the other chemicals to which you are exposed, and your 

individual characteristics such as age, gender, nutritional status, family traits, life-style, and state of 

health. 

1.1 WHAT IS HMX? 

HMX, an acronym for High Melting eXplosive, is also known as octogen and cyclotetramethylenetetranitramine, as well as by other names. It is a colorless solid that dissolves slightly in water. Only 

a very small amount of HMX will evaporate into the air; however, it can occur in air attached to 

suspended particles or dust. The taste and smell of HMX are not known. 

HMX is a manmade chemical and does not occur naturally in the environment. It is made from other 

chemicals known as hexamine, ammonium nitrate, nitric acid, and acetic acid. HMX explodes 
HMX 2 

1. PUBLIC HEALTH STATEMENT 

violently at high temperatures (534°F and above). Because of this property, HMX is used in nuclear 

devices, plastic explosives, rocket fuels, and burster chargers. A small amount of HMX is also formed 

in making cyclotrimethylene-trinitramine (RDX), another explosive similar in structure to HMX. The 

amount of HMX made and used in the United States at present is not known, but it is believed to be 

greater than 30 million pounds per year. 

More information about the chemical names, properties, and uses of HMX is in Chapters 3 and 4. 

1.2 WHAT HAPPENS TO HMX WHEN IT ENTERS THE ENVIRONMENT? 

Most of the HMX that enters the environment is released into waste water from places that make or 

use HMX. A small amount of HMX can be released to the air as dust or ash from facilities that burn 

waste contaminated with HMX. Some HMX may be released to soil as a result of accidental spills, 

the settling of HMX-containing dust particles from the air, or the disposal of waste that contains HMX 

in landfills. 

Dust particles containing HMX may be carried by the wind for some distance. The distance depends 

on a number of factors, including particle size, wind velocity, and weather conditions. Eventually, 

these particles settle to the earth, depositing on soil and surface waters. The length of time that HMX 

remains in the air is not known. 

In surface water, HMX does not evaporate or bind to sediments to any large extent. Sunlight breaks 

down most of the HMX in surface water into other compounds, usually in a matter of days to weeks. 

The amount of time HMX remains in surface water depends on how much light-absorbing material is 

present. A small amount of HMX may also be broken down by bacteria in the water. Some of the 

breakdown products of HMX (nitrite, nitrate, formaldehyde, l,l-dimethylhydrazine) are also harmful to 

your health, although the amounts you may be exposed to as a result of HMX in your drinking water 

are not expected to be above trace levels. 

Laboratory studies show that HMX is likely to move from soil into groundwater, particularly in sandy 

soils. For most soils, however, the movement of HMX into groundwater is expected to be slow. 

Bacteria in the soil are not expected to break down HMX to any large extent. Exactly how long HMX 
HMX 3 

1. PUBLIC HEALTH STATEMENT 

will remain in the environment is not known; however, HMX in soil and groundwater is expected to 

stay there for a long time. 

It is not known if plants, fish, or animals living in areas contaminated with HMX build up high levels 

of the chemical in their tissues. 

More information on what happens to HMX when it enters the environment is in Chapters 4 and 5. 

1.3 HOW MIGHT I BE EXPOSED TO HMX? 

There is no information on how often you might be exposed to HMX in the environment or to how 

much. Most people, however, probably won’t be exposed to HMX from the environment. People 

who work at facilities that make or use HMX or RDX, such as military personnel, may be exposed. 

These workers may be exposed by inhaling dusts that contain HMX or by getting HMX-containing 

liquids on their skin. People who live near facilities that make or use HMX, or near hazardous waste 

sites that contain HMX, may also be exposed. For these residents, exposure (if any) is most likely to 

occur from contaminated groundwater. However, exposures to small amounts of HMX from 

contaminated surface water, soil, and air are also possible. 

More information on how you can be exposed to HMX is in Chapter 5. 

1.4 HOW CAN HMX ENTER AND LEAVE MY BODY? 

HMX can enter your body if you breathe contaminated air, swallow contaminated water or soil, or get 

substances that contain HMX on your skin. Very little is known about how much and how fast HMX 

enters your body after you are exposed. 

Limited information from laboratory studies in animals suggests that if you swallow HMX, only a 

small amount (less than 5 percent) will be absorbed into your blood. The rest of the HMX that is not 

absorbed leaves your body in your feces, usually within a day or two after you are exposed. Your 

blood carries the small amount of absorbed HMX to your tissues. Animal studies suggest that the 
HMX 4 

1. PUBLIC HEALTH STATEMENT 

resulting concentrations of HMX in your lungs, liver, heart, and kidneys may be slightly higher than 

the concentrations in other tissues. 

HMX does not remain in any of your tissues for very long. Information from animal studies suggests 

that your body can transform HMX into other compounds called metabolites. At present, the identity 

and toxicity of these metabolites are not known. Most of these metabolites leave your body in your 

urine, usually within a few days after you are exposed. Smaller amounts of these metabolites may be 

released in your feces or in the air you breathe out. 

More information on how HMX enters and leaves your body is in Chapter 2. 

1.5 HOW CAN HMX AFFECT MY HEALTH? 

Information on the adverse health effects of HMX is limited. In one human study, no adverse effects 

were reported in workers exposed to HMX in air. However, the concentrations of HMX in the 

workplace air were not reported in this study, and only a small number of workers and effects were 

investigated. 

Studies in rats, mice, and rabbits indicate that HMX may be harmful to your liver and central nervous 

system if it is swallowed or gets on your skin. The lowest dose producing any effects in animals was 

100 milligrams per kilogram of body weight per day (mg/kg/day) orally and 165 mg/kg/day on the 

skin. Limited evidence suggests that even a single exposure to these dose levels harmed rabbits. The 

mechanism by which HMX causes adverse effects on the liver and nervous system is not understood. 

The reproductive and developmental effects of HMX have not been well studied in humans or animals. 

At present, the information needed to determine if HMX causes cancer is insufficient. Due to the lack 

of information, EPA has determined that HMX is not classifiable as to its human carcinogenicity. 

More information on how HMX can affect your health is in Chapter 2. 
HMX 5 

1. PUBLIC HEALTH STATEMENT 

1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 

EXPOSED TO HMX? 

You can find out if you have been exposed to HMX by having your blood, urine, or feces tested for 

HMX. Since HMX is poorly absorbed after it is swallowed, the levels of HMX in your blood and 

urine are likely to be lower than those in your feces. For best results, tests for HMX should be done 

within a few days after you are exposed. These tests cannot be used to tell how much HMX you have 

been exposed to or to predict whether or not you will experience adverse health effects. These tests 

are not usually done in a doctor’s office, but require that the samples be sent to a laboratory for 

testing. 

More information on medical tests to determine whether you have been exposed to HMX is in 

Chapters 2 and 6. 

1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 

PROTECT HUMAN HEALTH? 

The federal government has made several regulations and guidelines to protect human health. EPA 

recommends that the concentration of HMX in an adult’s drinking water be less than 0.40 milligrams 

per liter (mg/L) for a lifetime exposure. EPA regulates waste containing HMX as hazardous and has 

set restrictions on its disposal in landfills. The Department of State regulates the exportation of HMX, 

and the Department of Transportation regulates its transportation. The Bureau of Alcohol, Tobacco, 

and Firearms regulates the importation, manufacture, distribution, and storage of HMX. 

More information on government regulations and guidelines for HMX is in Chapter 7. 

1.8 WHERE CAN I GET MORE INFORMATION? 

If you have any more questions or concerns, please contact your community or state health or 

environmental quality department or: 
HMX 6 

1. PUBLIC HEALTH STATEMENT 

Agency for Toxic Substances and Disease Registry
 

Division of Toxicology
 

1600 Clifton Road NE, E-29
 

Atlanta, Georgia 30333
 

(404) 639-6000 

This agency can also provide you with information on the location of occupational and environmental 

health clinics. These clinics specialize in the recognition, evaluation, and treatment of illness resulting 

from exposure to hazardous substances. 
HMX 7 

2. HEALTH EFFECTS 

2.1 INTRODUCTION 

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 

other interested individuals and groups with an overall perspective on the toxicology of HMX. It 

contains descriptions and evaluations of toxicological studies and epidemiological investigations and 

provides conclusions, where possible, on the relevance of toxicity and toxokinetic data to public 

health. 

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 

2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 

To help public health professionals and others address the needs of persons living or working near 

hazardous waste sites, the information in this section is organized first by route of exposure ­

inhalation, oral, and dermal; and then by health effect - death, systemic, immunological, neurological, 

reproductive, developmental, genotoxic, and carcinogenic effects. These data are discussed in terms of 

three exposure periods - acute (14 days or less), intermediate (15-364 days), and chronic (365 days 

or more). 

Levels of significant exposure for each route and duration are presented in tables and illustrated in 

figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowestobservedadverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 

studies. LOAELs have been classified into “less serious” or “serious” effects. “Serious” effects are 

those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute 

respiratory distress or death). “Less serious” effects are those that are not expected to cause significant 

dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR 

acknowledges that a considerable amount of judgment may be required in establishing whether an end 

point should be classified as a NOAEL, “less serious” LOAEL, or “serious” LOAEL, and that in some 

cases, there will be insufficient data to decide whether the effect is indicative of significant 

dysfunction. However, the Agency has established guidelines and policies that are used to classify 
HMX 8 

2. HEALTH EFFECTS 

these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt 

at distinguishing between “less serious” and “serious” effects. The distinction between “less serious” 

effects and “serious” effects is considered to be important because it helps the users of the profiles to 

identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should 

also help in determining whether or not the effects vary with dose and/or duration, and place into 

perspective the possible significance of these effects to human health. 

The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 

figures may differ depending on the user’s perspective. Public health officials and others concerned 

with appropriate actions to take at hazardous waste sites may want information on levels of exposure 

associated with more subtle effects in humans or animals or exposure levels below which no adverse 

effects have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels 

or MRLs) may be of interest to health professionals and citizens alike. 

Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have 

been made for HMX. An MRL is defined as an estimate of daily human exposure to a substance that 

is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified 

duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target 

organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of 

exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic 

effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation 

and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 

Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 

uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 

uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 

example, acute inhalation MRLs may not be protective for health effects that are delayed in 

development or are acquired following repeated acute insults, such as hypersensitivity reactions, 

asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to 

assess levels of significant human exposure improve, these MRLs will be revised. 

A User’s Guide has been provided at the end of this profile (see Appendix B). This guide should aid 

in the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
HMX 9 

2. HEALTH EFFECTS 

2.2.1 Inhalation Exposure 

2.2.1.1 Death 

No studies were located regarding death in humans or animals after inhalation exposure to HMX. 

2.2.1.2 Systemic Effects 

No studies were located regarding respiratory, cardiovascular, gastrointestinal, musculoskeletal, dermal, 

or ocular effects in humans or animals after inhalation exposure to HMX. Data regarding the 

hematological, hepatic, and renal effects of HMX in humans are limited to a single study. This study 

is discussed below. 

Hematological Effects. A single study investigated the hematological effects of HMX in 24 male 

munitions workers who were also exposed to cyclotrimethylenetrinitramine (RDX) (Hathaway and 

Buck 1977). Compared to an unexposed control group (237 males), there were no significant 

differences in hemoglobin, hematocrit, and reticulocyte count in blood samples from workers exposed 

to HMX and RDX. Although levels of RDX in air were measured in this study (mean = 0.28 mg/m3

), 

the levels of HMX in the air of the munitions plant were not determined. 

No studies were located regarding hematological effects in animals after inhalation exposure to HMX. 

Hepatic Effects. A single study investigated the hepatic effects of HMX in 24 male munitions 

workers who were also exposed to a mean concentration of 0.28 mg/m3

 RDX (Hathaway and Buck 

1977). Compared to an unexposed control group (237 males), there were no significant differences in 

lactate dehydrogenase, alkaline phosphatase, serum glutamic oxaloacetic transaminase, or serum 

glutamic pyruvic transaminase activities. Since this study was originally conducted to investigate the 

effects of RDX, the levels of HMX in the air of the munitions plant were not determined. 

No studies were located regarding hepatic effects in animals after inhalation exposure to HMX. 
HMX 10 

2. HEALTH EFFECTS 

Renal Effects. A single study investigated the renal effects of HMX in 24 male munitions workers 

who were also exposed to a mean concentration of 0.28 mg/m3 RDX (Hathaway and Buck 1977). 

Compared to an unexposed control group (237 males), there were no significant differences in blood 

urea nitrogen concentration. Since this study was originally conducted to investigate the effects of 

RDX, the levels of HMX in the air of the munitions plant were not determined. 

No studies were located regarding renal effects in animals after inhalation exposure to HMX. 

2.2.1.3 Immunological and Lymphoreticular Effects 

A single study investigated the immunological effects of explosives in a group of 558 male and female 

munitions workers (Hathaway and Buck 1977). The study was prompted by the occurrence of three 

cases of lupus erythematosus at one munitions plant within a 2-year period. The workers were 

exposed to RDX and HMX either alone or in combination with other explosives such as 

trinitrotoluene. Compared to an unexposed control group (863 males and females), the prevalence of 

antinuclear antibodies (a biomarker for lupus erythematosus) was not significantly different in exposed 

workers. Although the levels of RDX were determined to range up to 1.57 mg/m3

 (mean = 

0.28 mg/m3

) in the air of one munitions plant, the levels of HMX in air were not determined. 

No studies were located regarding immunological and lymphoreticular effects in animals after 

inhalation exposure to HMX. 

No studies were located regarding the following effects in humans or animals after inhalation exposure 

to HMX: 

2.2.1.4 Neurological Effects 

2.2.1.5 Reproductive Effects 

2.2.1.6 Developmental Effects 

2.2.1.7 Genotoxic Effects 

Genotoxicity studies are discussed in Section 2.5. 
HMX 11 

2. HEALTH EFFECTS 

2.2.1.8 Cancer 

No studies were located regarding carcinogenic effects in humans and animals after inhalation 

exposure to HMX. 

2.2.2 Oral Exposure 

2.2.2.1 Death 

No studies were located regarding death in humans after oral exposure to HMX. 

Several studies in animals indicate that acute and intermediate oral exposure to HMX can be lethal. 

For single exposures, LD50 values of 5,500 and 6,400 mg/kg HMX were reported for male and female 

rats, respectively (Army 1985h). In mice, the LD50 values were 1,700 and 3,200 mg/kg HMX for 

males and females, respectively (Army 1985h). Limited evidence suggests that rabbits may be more 

sensitive to the lethal effects of HMX than rodents. Deaths in rabbits were observed following single 

oral doses of 100 mg/kg or more (Army 1985h). However, there are several deficiencies in this Army 

(1985h) study that preclude establishing a definitive conclusion. For instance, the gavage 

administration of the HMX may have contributed to the apparent greater susceptibility of the rabbits as 

a result of a bolus effect. Also, only a small number of rabbits were tested (two per group), and no 

control group was run concurrently. The authors concluded that HMX was relatively nontoxic to rats, 

slightly toxic to mice, and toxic to rabbits. Deaths were observed in rats exposed to 

3,055-8,054 mg/kg/day HMX and in mice exposed to 300-800 mg/kg/day for 14 days (Army 1985d, 

1985e). In mice, the males appeared to be more sensitive to the lethal effects of HMX since 5/6 males 

died following exposure to 300 mg/kg/day, whereas only 2/6 females died following exposure to 

800 mg/kg/day. In rats, the females appeared to be more sensitive than male rats to the lethal effects 

of HMX, since 6/6 females died following exposure to 3,055 mg/kg/day, compared to 5/6 males 

following exposure to 8,504 mg/kg/day. No treatment-related deaths were observed in rats exposed to 

up to 4,000 mg/kg/day HMX for 13 weeks (Army 1985b). However in mice, deaths were noted in 

13/20 males exposed to 200 mg/kg/day and in 12/20 females exposed to 250 mg/kg/day HMX for 

13 weeks (Army 1985b). All LOAEL values from each reliable study for death are recorded in 

Table 2-l and plotted in Figure 2-l. 







HMX 19 

2. HEALTH EFFECTS 

2.2.2.2 Systemic Effects 

No studies were located regarding systemic effects in humans after oral exposure to HMX. Studies 

regarding systemic effects in animals are summarized below. The highest NOAEL values and all 

LOAEL values from each reliable study for systemic effects in animals are recorded in Table 2-1 and 

plotted in Figure 2- 1. 

Respiratory Effects. No studies were located regarding respiratory effects in humans after oral 

exposure to HMX. Following exposure to a single oral dose of 5,447, 1,626, and 50 mg/kg HMX in 

rats, mice, and rabbits, respectively, a “reddening” of the lungs was observed (Army 1985h). White 

nodules were also noted in the lungs of one exposed rabbit. Both lesions were not described further 

by the authors; therefore, their significance is uncertain. Furthermore, the rabbit study contained a 

number of design limitations (small number of animals, no control group). No gross or 

histopathological lesions were observed in the lungs of mice exposed to 90 mg/kg/day HMX in the 

diet for 13 weeks (Army 1985b). Pulmonary function was not investigated in any of the animals. The 

data are too limited to draw firm conclusions, but suggest that rabbits may be more susceptible than 

rats and mice to the acute pulmonary effects of HMX. 

Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after 

oral exposure to HMX. No gross or histopathological lesions of the heart were observed in mice 

exposed to 5,000 mg/kg/day HMX for 14 days (Army 1985d). Similarly, no effects were noted on the 

heart in mice exposed to 90 mg/kg/day HMX for 13 weeks (Army 1985b). The data suggest that the 

heart is not a critical target of HMX toxicity. 

Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after 

oral exposure to HMX. A “white fluid” was noted in the gastrointestinal tract of rats and mice 

exposed to a single oral dose of 5,447 and 1,626 mg/kg HMX, respectively (Army 198%). The fluid 

was not described further; therefore its significance is uncertain. No gross or histopathological lesions 

were observed in the gastrointestinal tract of mice exposed to 90 mg/kg/day HMX in the diet for 

13 weeks (Army 1985b). Although the data suggest that high doses of HMX may adversely affect the 

gastrointestinal system, the gastrointestinal tract may not be affected by relatively low doses of HMX. 
HMX 20 

2. HEALTH EFFECTS 

Hematological Effects. No studies were located regarding hematological effects in humans after 

oral exposure to HMX. A statistically significant decrease in hemoglobin and packed cell volume, and 

a nonsignificant increase in methemoglobin were noted in female rats exposed to 1,500 mg/kg/day in 

the diet for 13 weeks (Army 1985c). A significant elevation in methemoglobin concentration was 

observed in male rats exposed to 4,000 mg/kg/day (Army 1985c). No significant hematological effects 

were noted in mice exposed to 750 mg/kg/day HMX for 13 weeks (Army 1985b). The data suggest 

that mild hematological effects may occur following exposure to large doses of HMX, but that these 

effects may not be of concern following exposure to relatively low doses of HMX. 

Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 

after oral exposure to HMX. Data regarding the musculoskeletal effects of HMX in animals are 

limited to a single study. No gross or histopathological lesions were noted in the bones or skeletal 

muscle of mice exposed to 90 mg/kg/day HMX for 13 weeks (Army 1985b). The data suggest that 

musculoskeletal effects are not of concern following exposure to relatively low doses of HMX, but this 

has not been well studied. 

Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure to 

HMX. Several studies have reported hepatic effects in animals following exposure to HMX. 

Hepatocyte hyperplasia and cytoplasmic eosinophilia were noted in rats and mice exposed to 1,280 and 

300 mg/kg/day HMX, respectively, for 14 days (Army 1985d, 1985e). Clear evidence of 

hepatotoxicity was observed at a higher dose of 8,504 mg/kg/day HMX, which resulted in 

centrilobular degeneration in male rats exposed for 14 days (Army 1985e). Hepatic effects were not 

observed in control animals. The centrilobular cells of male rats exposed to 150 mg/kg/day HMX for 

13 weeks were enlarged with pale nuclei and dark cytoplasm (Army 1985c). Higher doses of 

1,500 mg/kg/day (females) and 4,000 mg/kg/day (males) produced significant elevations in serum 

alkaline phosphatase levels in rats, while serum aspartate aminotransferase, serum alanine amino 

transferase, and lactate dehydrogenase levels showed no consistent change. No hepatic effects were 

observed in male and female rats exposed to 50 mg/kg/day HMX, in female mice exposed to 

90 mg/kg/day HMX, and in male mice exposed to 75 mg/kg/day HMX for 13 weeks (Army 1985b, 

1985c). Histopathology was not performed on mice exposed to doses greater than 90 mg/kg/day 

(females) or 75 mg/kg/day (males). Since deaths occurred in these animals, a histological examination 

may have indicated whether or not there were any hepatic lesions. 
HMX 21 

2. HEALTH EFFECTS 

Some of the hepatic effects observed in animals (hepatocyte hyperplasia, cytoplasmic eosinophilia, 

centrilobular cell enlargement) may represent an adaptive response of the liver rather than a toxic 

response. Adaptive responses may result in changes that are beneficial or potentially detrimental to 

the host. However, given that the borderline between adaptive physiology and toxicity is not always 

well defined, and that such changes may be predictive of effects which are clearly toxic (centrilobular 

degeneration), it is best to consider these changes as less serious adverse effects. Collectively, the data 

from animal studies indicate that the liver is adversely affected by exposure to moderate to high doses 

of HMX. Based on the NOAEL of 50 mg/kg/day in rats, an intermediate oral MRL of 

0.05 mg/kg/day was calculated as described in footnote “d” of Table 2-l. 

Renal Effects. No studies were located regarding renal effects in humans after oral exposure to 

HMX. Data regarding the renal effects of HMX in animals are limited. The kidneys of rats 

administered a single dose of 5,447 mg/kg HMX were “pale” in appearance (Army 1985h). This 

effect was not described further by the authors, therefore its significance is uncertain. Congestion of 

the kidney was noted in some rats exposed to 1,280 mg/kg/day or more (Army 1985e). However, no 

gross or histopathological lesions of the kidney developed in mice exposed to up to 5,000 mg/kg/day 

HMX for 14 days (Army 1985d). Focal tubular atrophy, dilatation, and increased kidney weights were 

observed in female rats exposed to 270 mg/kg/day HMX, while blood urea nitrogen was elevated in 

female rats exposed to 1,500 mg/kg/day HMX in the diet for 13 weeks (Army 1985c). In the same 

study, decreased pH, increased volume, and crystal formation was observed in the urine of male and 

female rats exposed to 1,500-4,000 mg/kg/day HMX. No gross or histopathological lesions of the 

kidney were observed in female rats exposed to 115 mg/kg/day or in female mice exposed to 

90 mg/kg/day for 13 weeks (Army 1985b, 1985c). No gross or histopathological effects were 

observed in male rats exposed to 4,000 mg/kg/day HMX or in male mice exposed to 75 mg/kg/day 

HMX for 13 weeks. Histopathological examinations were not performed in male mice exposed to 

doses greater than 75 mg/kg/day HMX, or female mice exposed to doses greater than 90 mg/kg/day. 

The data suggest that moderate to high doses of HMX may adversely affect the kidney, but that 

relatively low doses of HMX are without effect. 

Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to 

HMX. Data regarding the dermal effects of HMX in animals are limited to one study. No gross or 

histopathological lesions of the skin developed in mice exposed to 90 mg/kg/day HMX for 13 weeks 
HMX 22 

2. HEALTH EFFECTS 

(Army 1985b). Data suggest that the skin is not an important target of HMX toxicity following 

ingestion. 

Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to 

HMX. Data regarding the ocular effects of HMX in animals are limited to one study. Ophthalmoscopic 

examinations did not reveal any treatment-related effects on the eyes of rats exposed to up to 

4,000 mg/kg/day HMX for 13 weeks (Army 1985c). 

Body Weight Effects. No studies were located regarding body weight effects in humans after oral 

exposure to HMX. A decrease in body weight gain of 19% was observed in rats exposed to 

370 mg/kg/day HMX in the diet for 14 days (Army 1985e). Body weights were decreased in a dosedependent 

manner in male and female rats exposed to 50-4,000 mg/kg/day for 13 weeks (Army 

1985c). However, the dose at which this effect became significant could not be determined. Food 

intake of the animals in both studies was depressed. Although food intake was also decreased in mice 

exposed to 750 mg/kg/day HMX for 13 weeks, no significant change in body weight gain was noted 

(Army 1985b). These data are inconsistent, therefore no firm conclusions can be made. 

2.2.2.3 Immunological and Lymphoreticular Effects 

No studies were located regarding immunological and lymphoreticular effects in humans after oral 

exposure to HMX. 

Lymphocytic depletion of the thymus and spleen was noted in rats and mice exposed to 1,280 and 

300 mg/kg/day, respectively for 14 days (Army 1985d, 1985e). Effects were not observed in animals 

in the control group. The absolute and relative spleen weights were decreased in a dose-dependent 

manner in male rats exposed to 50 mg/kg/day HMX or more for 13 weeks (Army 1985c). However, 

significant body weight changes occurred in these animals, and therefore these effects are difficult to 

interpret. Collectively, the data suggest that perhaps even low doses of HMX can adversely affect 

organs important to the immune system; however, none of the studies investigated the effects of HMX 

on immune system function. The highest NOAEL values and all LOAEL values for immunological 

effects in animals are recorded in Table 2-l and plotted in Figure 2-l. 
HMX 23 

2. HEALTH EFFECTS 

2.2.2.4 Neurological Effects 

No studies were located regarding neurological effects in humans after oral exposure to HMX. 

Several studies have reported neurological effects in animals after acute exposure to HMX. A single 

dose of 2,421 or 956 mg/kg HMX produced hyperkinesia in rats and mice, respectively (Army 1985h). 

The authors of this study also reported hypokinesia and ataxia in rats and mice exposed to higher 

doses (5,447 and 1,626 mg/kg, respectively) of HMX. Mild convulsions, hyperkinesia, and mydriasis 

(dilated pupils) occurred in rabbits following a single oral dose of 50 mg/kg HMX or more (Army 

1985h). However, limitations in this study (only a small number of rabbits were tested and no control 

group was run concurrently) detract from the significance of these findings. In addition, gavage 

administration of the HMX may have contributed to the apparent greater susceptibility of the rabbits as 

a result of a bolus effect. Congestion and hemorrhaging of the blood vessels in the brain was noted in 

some rats exposed to 8,504 mg/kg/day HMX for 14 days (Army 1985e). Hyperkinesia and excitability 

when aroused were noted in mice exposed to 100 mg/kg/day HMX in the diet for 14 days (Army 

1985d). A NOAEL was not identified in this study. Doses of 300 mg/kg/day HMX produced 

convulsions, a hunched posture, piloerection, and increased sensitivity to audio stimuli in some of the 

mice from this study. Collectively, these data suggest that the central nervous system is an important 

target of HMX toxicity. Based on the LOAEL of 100 mg/kg/day in mice, an acute oral MRL of 

0.1 mg/kg/day was calculated as described in footnote “c” of Table 2-l. All LOAEL values for 

neurological effects in animals are recorded in Table 2-l and plotted in Figure 2-l. 

2.2.2.5 Reproductive Effects 

No studies were located regarding reproductive effects in humans after oral exposure to HMX. 

No gross or histopathological lesions were observed in the ovaries or testes of mice exposed to 

90 mg/kg/day HMX in the diet for 13 weeks (Army 1985b). Mice exposed to higher doses of HMX 

in this study were not histopathologically examined. Reproductive function was not assessed in this 

study, therefore no firm conclusions can be made regarding the potential of HMX in producing 

reproductive effects. The NOAEL value for reproductive organ histopathology is recorded in 

Table 2-l and plotted in Figure 2-l. 
HMX 24 

2. HEALTH EFFECTS 

2.2.2.6 Developmental Effects 

No studies were located regarding developmental effects in humans or animals after oral exposure to 

HMX. 

2.2.2.7 Genotoxic Effects 

No studies were located regarding genotoxic effects in humans or animals after oral exposure to HMX. 

Genotoxicity studies are discussed in Section 2.5. 

2.2.2.8 Cancer 

No studies were located regarding carcinogenic effects in humans or animals after oral exposure to 

HMX. 

2.2.3 Dermal Exposure
 

2.2.3.1 Death
 

No studies were located regarding death in humans after dermal exposure to HMX.
 

The dermal LD50 values for HMX in rabbits were reported to be 634 mg/kg in males and 7 19 mg/kg 

in females (Army 1985h). The LD50values were slightly higher (and therefore less toxic) in rabbits 

with abraded skin. The reason for this unexpected difference in HMX toxicity between rabbits with 

abraded versus nonabraded skin is not readily apparent. No deaths were observed in rabbits and rats 

exposed to 372 and 4,230 mg/kg HMX, respectively (Army 1985h). Exposure to 165 mg/kg/day 

HMX in dimethylsulfoxide for up to 5 days caused deaths in 3/10 exposed rabbits (Army’ 1974). The 

same dose produced 3/6 deaths in rabbits exposed for 4 weeks (Army 1974). The data indicate that 

dermal exposure to HMX can be lethal to rabbits. All LOAEL values for death in animals are 

recorded in Table 2-2. 



HMX 28 

2. HEALTH EFFECTS 

2.2.3.2 Systemic Effects 

No studies were located regarding systemic effects in humans after dermal exposure to HMX. Data 

regarding the systemic effects of HMX in animals are discussed below. The highest NOAEL values 

and all LOAEL values for systemic effects in animals are recorded in Table 2-2. 

Respiratory Effects. No studies were located regarding respiratory effects in humans after dermal 

exposure to HMX. Congestion and “reddening” of the trachea and lungs were observed in rabbits 

dermally exposed to a single dose of 168 mg/kg HMX (Army 1985h). The nature of the “reddening” 

was not discussed further by the authors, therefore its significance is uncertain. Pulmonary function 

was not evaluated in these animals. No gross or histopathological lesions of the lungs were noted in 

three rabbits that died following exposure to 165 mg/kg/day HMX solution for 4 weeks (Army 1974). 

These data are too limited to draw firm conclusions regarding the respiratory effects of HMX after 

dermal exposure. 

Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after 

dermal exposure to HMX. Data regarding the cardiovascular effects of HMX in animals are limited to 

a single study. Consistent changes in blood pressure, heart rate, and electrocardiogram readings were 

not observed in groups of l-2 dogs exposed to up to 480 mg/kg/day for l-5 days or 289 mg/kg/day 

for 4 weeks (Army 1974). No gross or histopathological lesions of the heart were noted in three 

rabbits that died after exposure to 165 mg/kg/day HMX in solution for 4 weeks (Army 1974). 

However, due to the small number of animals tested, these studies may not have had the statistical 

power to detect any subtle effects of HMX on the cardiovascular system. These data are too limited to 

draw firm conclusions on the potential cardiovascular effects of HMX, but suggest that the heart is not 

particularly sensitive. 

Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans or 

animals after dermal exposure to HMX. 
HMX 29 

2. HEALTH EFFECTS 

Hematological Effects. No studies were located regarding hematological effects in humans after 

dermal exposure to HMX. Data regarding the hematological effects of HMX in animals are limited to 

a single study. No changes were noted for a large number of hematological parameters in rabbits 

exposed to a single dermal exposure to 165 mg/kg of HMX in solution (Army 1974). Although 

limited, the data from this study suggest that the blood is not particularly sensitive to the toxic effects 

of HMX. 

Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 

after dermal exposure to HMX. Data regarding the musculoskeletal effects of HMX in animals are 

limited to a single study. No gross or histopathological lesions were observed in the muscle or bone of 

rabbits exposed to 165 mg/kg/day of an HMX solution for 4 weeks (Army 1974). The data are too 

limited to draw firm conclusions, but suggest that muscle and bone tissue are not important targets of 

HMX toxicity. 

Hepatic Effects. No studies were located regarding hepatic effects in humans after dermal exposure 

to HMX. The livers of rabbits administered a single dermal dose of 372 mg/kg HMX were congested 

and mottled in appearance with prominent fissures (Army 1985h). No gross or histopathological 

lesions of the liver were observed in rabbits exposed to a single dose of 168 mg/kg HMX (Army 

1985h) or to 165 mg/kg/day HMX for 4 weeks (Army 1974). These data are too limited to make firm 

conclusions, but suggest that dermal exposure to HMX may adversely affect the liver. 

Renal Effects. No studies were located regarding renal effects in humans after dermal exposure to 

HMX. Following exposure to a single dermal dose of 168 mg/kg HMX, the kidneys of rabbits 

showed tubular dilation, fibrosis, and atrophy (Army 198511). Atrophy of the glomerulus was also 

noted. No gross or histopathological lesions of the kidney were observed in rabbits exposed to 

165 mg/kg/day HMX for 4 weeks (Army 1974). Although limited, these data suggest that the kidney 

may be adversely affected following dermal exposure to HMX. 

Dermal Effects. No studies were located regarding dermal effects in humans after dermal exposure 

to HMX. Several studies have reported dermal effects in animals following dermal exposure to HMX. 

Mild irritation of the skin was noted in rabbits after a single dermal exposure to 109 mg/kg HMX as a 

60% solution in dimethylsulfoxide (Army 1985h). Slight erythema was noted in guinea pigs after 

dermal application of 1,000 mg/kg/day HMX for l-3 days (Army 1974). No evidence of skin 
HMX 30 

2. HEALTH EFFECTS 

irritation was observed in guinea pigs exposed to dermal doses of 510 mg/kg/day HMX for l-3 days 

or in rabbits receiving a single dose of 165 mg/kg HMX (Army 1974). In addition, no evidence of 

dermal sensitization was noted in guinea pigs previously exposed to HMX and challenged with a 

single dermal dose of 357 mg/kg HMX (Army 1985h). Dermatitis was observed in rabbits 

administered 16.5 mg/kg/day HMX for 4 weeks, but not in guinea pigs receiving topical or intradermal 

doses of 196 mg/kg/day HMX, 3 times/week for 3 weeks (Army 1974). Although some studies 

reported dermal effects in animals exposed to HMX, some of these effects were attributed to the 

solvents used in HMX solutions (e.g., dimethylsulfoxide). Collectively, the data indicate that HMX 

may cause a mild irritation of the skin following direct exposure. 

Ocular Effects. No studies were located regarding ocular effects in humans after dermal exposure to 

HMX. Mild irritation of the conjunctiva was noted in rabbits after a single dermal exposure to 

109 mg/kg HMX as a 60% solution in dimethylsulfoxide (Army 1985h). 

2.2.3.3 Immunological and Lymphoreticular Effects 

No studies were located regarding immunological and lymphoreticular effects in humans after dermal 

exposure to HMX. 

A single study reported no evidence of dermal sensitization in guinea pigs challenged with a single 

application of a 60% solution of HMX (see Section 2.2.3.2). A single study reported a pale 

appearance and enlargement of the spleen in rabbits administered a single dermal dose of 168 mg/kg 

HMX or more (Army 1985h). Higher doses depleted the spleen of lymphocytes, red pulp, and white 

pulp. No other studies regarding the immunological effects of HMX in animals were located. The 

LOAEL value for immunological effects in animals is recorded in Table 2-2. 

2.2.3.4 Neurological Effects 

No studies were located regarding neurological effects in humans after dermal exposure to HMX. 

A number of neurological effects including hyperkinesia, hypokinesia, clonic convulsions, and changes 

in aggressive behavior were noted in rabbits administered a single dose of 168 mg/kg HMX or more 

(Army 1985h). An increase in the severity of the convulsions, hindleg paralysis, and perivascular 
HMX 31 

2. HEALTH EFFECTS 

cuffing in the brain was observed in rabbits exposed to 372 mg/kg HMX in this study. Other studies 

detected no consistent electroencephalogram abnormalities in beagle dogs exposed to 480 mg/kg/day 

for 3 days or to 289 mg/kg/day for 4 weeks (Army 1974); however, only a small number of dogs were 

used in this study. The data are too limited to draw firm conclusions, but suggest that the central 

nervous system may be a target of HMX toxicity. In addition, rabbits may be more sensitive than 

beagle dogs to the neurological effects of HMX. The highest NOAEL values and all LOAEL values 

from each reliable study for neurological effects in animals are recorded in Table 2-2. 

No studies were located regarding the following health effects in humans or animals after dermal 

exposure to HMX: 

2.2.3.5 Reproductive Effects 

2.2.3.6 Developmental Effects 

2.2.3.7 Genotoxic Effects 

Genotoxicity studies are discussed in Section 2.5. 

2.2.3.8 Cancer 

No studies were located regarding carcinogenic effects in humans or animals after dermal exposure to 

HMX. 

2. 3 TOXICOKINETICS 

No studies were located regarding toxicokinetics in humans after exposure to HMX. Limited 

information is available from studies in animals exposed to HMX by the oral and parenteral routes. 

These studies suggest that HMX is poorly absorbed in the gastrointestinal tract. Most of, an orally 

administered dose is excreted in the feces as unchanged HMX. The small amount of HMX that is 

absorbed in the body may be temporarily found at higher concentrations, particularly in the lungs, 

liver, heart, and kidneys. However, the levels of HMX in these tissues do not remain elevated for 

very long. Limited data indicate that HMX is readily metabolized to polar intermediates; however, 

these metabolites have not been identified. Most of an absorbed dose of HMX is excreted in the urine 
HMX 32 

2. HEALTH EFFECTS 

within 4 days. The mechanism of action for HMX in producing adverse effects may involve the 

formation of toxic metabolites; however, data regarding this possibility are generally lacking. 

2.3.1 Absorption 

2.3.1 .1 Inhalation Exposure 

No studies were located regarding absorption in humans or animals after inhalation exposure to HMX. 

2.3.1.2 Oral Exposure 

No studies were located regarding absorption in humans after oral exposure to HMX. 

Several studies investigated the oral absorption of HMX in animals. In rats and mice exposed to a 

single oral dose of 500 mg/kg HMX, peak plasma levels of 6-10 μg/mL were reached by 6 hours after 

exposure. These peak levels corresponded to <0.1% of the administered dose (Army 1986). Based on 

urinary and fecal excretion data, less than 15% of the dose was absorbed by rats, and less than 30% of 

the dose was absorbed by mice exposed to a single oral dose of 500 mg/kg (Army 1986). Based on a 

comparison of the levels of HMX in the plasma and urine following oral and intravenous exposures, 

the authors also concluded that <5% of the oral dose was absorbed. Plasma levels of HMX were 

relatively low and were not dependent on dose in rats administered 50-4,000 mg/kg/day HMX for 

13 weeks (Army 19858). The authors concluded that most of the administered dose was not 

systemically absorbed. Indirect evidence of a low absorption fraction for HMX can be inferred from 

the fact that LD50 values for intravenously administered HMX in rats are several orders of magnitude 

lower than those reported for oral exposures (Army 1985h). Collectively, the data from animal studies 

indicate that HMX is not well absorbed by the gastrointestinal tract. However, the absorption of HMX 

has not been investigated in what appears to be the most sensitive species, rabbits. Species differences 

in absorption may be responsible in part for differences observed in sensitivity to HMX. 

2.3.1.3 Dermal Exposure 

No studies were located regarding absorption in humans or animals after dermal exposure to HMX. 
HMX 33 

2. HEALTH EFFECTS 

2.3.2 Distribution 

2.3.2.1 Inhalation Exposure 

No studies were located regarding distribution in humans or animals after inhalation exposure to 

HMX. 

2.3.2.2 Oral Exposure 

No studies were located regarding distribution in humans after oral exposure to HMX. 

Limited information regarding the distribution of HMX is available from animal studies. Four days 

after a single oral dose of 500 mg/kg HMX, approximately 0.7% and 0.6% of the dose was retained in 

the bodies of exposed rats and mice, respectively (Army 1986). Plasma levels in rats administered 

50-4,000 mg/kg/day for 13 weeks ranged from 0.91-3.76 μg/mL, but were not increased in a dosedependent 

manner (Army 19858). However, in this study, low levels of HMX were also detected in 

the plasma of unexposed control rats. The authors offered no explanation for this occurrence; 

therefore, the validity of the results is questionable. Information regarding levels of HMX measured in 

specific organs was not provided. 

2.3.2.3 Dermal Exposure 

No studies were located regarding distribution in humans or animals after dermal exposure to HMX. 

2.3.2.4 Other Routes of Exposure 

No studies were located regarding distribution in humans after other routes of exposure to HMX. 

Data regarding distribution in animals after parenteral exposure to HMX are limited to a single study. 

Two minutes after a single intravenous dose of 2 mg/kg radiolabeled 14C-HMX was administered to 

rats, the highest levels of radioactivity (expressed in terms of μg/g) were detected in the lungs (15.39), 

while lower levels were detected in the heart (5.18), liver (4.25), kidney (3.96), whole blood (2.15), 

ovaries and uterus (2.03), spleen (1.87), thymus (1.74), plasma (1.58), skeletal muscle (1.28), bone 
HMX 34 

2. HEALTH EFFECTS 

(1.25), and gastrointestinal tract (1.23) (Army 1986). The lowest levels of radioactivity were detected 

in the fat (0.48), testes and seminal vesicles (0.22), and brain (0.22). By 96 hours after exposure, 

levels of radioactivity dropped considerably. Detectable levels were found in the kidney (0.36), 

thymus (0.30), and liver (0.26), while lower levels were found in the lung (0.19), spleen (0.18), 

ovaries and uterus (0.15), heart (0.13), fat (O.10), and bone (0.10). The lowest levels of radiolabel 

were detected in the testes and seminal vesicles (0.09), gastrointestinal tract (0.08), skeletal muscle 

(0.08), whole blood (0.07), plasma (0.05), and brain (0.04). Although the data are limited, they 

suggest that there is some preferential distribution of HMX in the body, particularly in the lungs, liver, 

heart, and kidney, but that these tissue levels do not remain elevated for very long after exposure. 

2.3.3 Metabolism 

No studies were located regarding metabolism in humans after exposure to HMX. 

Data regarding the metabolism of HMX in animals are extremely limited. A single study reported 

rapid metabolism of HMX in rats injected intravenously with 2 mg/kg 14C-HMX (Army 1986). 

Analysis of urine, feces, plasma, and tissues revealed the presence of very polar metabolites of HMX. 

Although these metabolites were not identified, chromatographic analysis of the urine revealed the 

presence of at least two metabolites. Following doses of 5-750 mg/kg/day HMX in the diet for 

13 weeks, the stomach contents of exposed mice were analyzed for nitrite content (Army 1985a). The 

nitrite content of the stomach (0.1-l .l μg/g) was not elevated above levels expected to arise from 

normal dietary contributions. The authors concluded that nitrite was not released from HMX in the 

stomach to any significant extent. However, the extent to which nitrite is released after HMX is 

absorbed into the blood was not investigated. No other studies were located regarding the metabolism 

of HMX. 

2.3.4 Excretion 

2.3.4.1 Inhalation Exposure 

No studies were located regarding excretion in humans or animals after inhalation exposure to HMX. 
 

HMX 35 

2. HEALTH EFFECTS 

2.3.4.2 Oral Exposure 

No studies were located regarding excretion in humans after oral exposure to HMX. 

Four days after a single oral dose of 500 mg/kg 14C-HMX, most of the dose (approximately 85% and 

70%) was excreted in the feces of exposed rats and mice, respectively (Army 1986). Smaller fractions 

of the dose were eliminated in the urine (3-4%) and expired air (0.5-l%) of exposed animals. 

Although these studies suggest that most of an administered dose of HMX is excreted in the feces, 

fecal excretion most likely represents the fraction of the dose that is not absorbed in the 

gastrointestinal tract. Other studies indicate that the majority of an absorbed dose of HMX is excreted 

in the urine (see Section 2.3.4.4). 

2.3.4.3 Dermal Exposure 

No studies were located regarding excretion in humans or animals after dermal exposure to HMX. 

2.3.4.4 Other Routes of Exposure 

No studies were located regarding excretion in humans after other routes of exposure to HMX. 

Data regarding excretion in animals injected with HMX are limited to a single study. In rats 

administered a single intravenous dose of 2 mg/kg HMX, approximately 3% of the dose was excreted 

in the feces, 61% was excreted in the urine within 4 days, and 6% of the dose was released in expired 

air within 2 days after exposure (Army 1986). Although 24% of the dose was not accounted for in 

this study, the data suggest that most of an absorbed dose of HMX is excreted in the urine. Biliary 

excretion does not appear to contribute significantly to the fecal excretion of HMX after oral exposure. 

2.4 MECHANISMS OF ACTION 

The mechanism of action for the absorption and distribution of HMX has not been studied. Based on 

the physical properties of HMX (see Chapter 3), these processes most likely occur by passive 

diffusion. 
HMX 36 

2. HEALTH EFFECTS 

The mechanism of action for HMX in producing adverse effects has not been studied in humans or 

animals. One possible mechanism of action involves the generation of toxic intermediates during the 

metabolism of HMX. Although the metabolites of HMX have not been characterized, some possible 

metabolites include nitrite and hydrazines. Speculative mechanisms involving the formation of these 

metabolites are discussed below. 

Potentially, four molecules of nitrite could be released from each molecule of HMX as a result of 

cleavage of the nitrogen-nitrogen bond at the l-, 3-, 5-, and 7-positions. Studies in animals have 

reported methemoglobin formation (Army 1985c) and cardiovascular collapse (Army 1974) following 

exposure to HMX. Both effects are similar to effects observed in animals exposed to nitrite. 

Although the stomach contents of HMX-exposed mice did not contain levels of nitrite that were 

elevated above levels detected in control mice (Army 1985a), the possibility remains for the liberation 

of nitrite after HMX is absorbed and metabolized in the body. 

Hydrazines such as l,l-dimethylhydrazine, 1-methylhydrazine, and hydrazine could be formed as a 

result of nitroreduction of the nitro groups in HMX to amines, followed by ring cleavage at the 

carbon-nitrogen bonds. Some microorganisms are capable of forming l,l-dimethylhydrazine from 

HMX (see Section 5.3.2.2), therefore it is possible that some mammalian enzyme systems possess 

similar metabolic abilities. Hydrazines are known to adversely affect the central nervous system and 

the liver (ATSDR 1993). Reactions with pyridoxine (vitamin B6) and the generation of reactive 

intermediates have been implicated in the mechanism of action for hydrazines (ATSDR 1993). It is 

possible that the neurological and hepatic effects of HMX are attributable to the formation of 

hydrazines in the body. This mechanism is purely speculative and has not been studied, yet it parallels 

that observed for the structurally related explosive, RDX. 

2.5 RELEVANCE TO PUBLIC HEALTH 

HMX is used in the manufacture of explosives. People may be exposed to HMX if they .work at 

facilities which manufacture, process, or use HMX. People who live near these facilities, near 

accidental spills, or near hazardous waste sites contaminated with HMX may also be exposed. 
HMX	 37 

2. HEALTH EFFECTS 

The toxicity of HMX in humans has not been well studied. A single human study reported no adverse 

effects in munitions workers exposed to an undetermined concentration of HMX in air. However, the 

number of subjects and end points evaluated in this study were limited. 

The toxicity of HMX has been investigated in animals primarily exposed by the oral route. These 

studies indicate that the central nervous system and liver are the primary targets of HMX toxicity 

following acute and intermediate exposures. Neurological effects noted include hyperkinesia, 

hypokinesia, and convulsions. Hepatic effects noted include hepatocyte hyperplasia, cytoplasmic 

eosinophilia, mottled appearance, and centrilobular degeneration. The mechanism by which HMX 

produces these effects is not well understood. There appear to be some species- and sex-dependent 

differences regarding the sensitivity to HMX-mediated lethal and neurological effects. However, since 

these effects have only been described in animals, their relevance to human exposures to HMX is 

uncertain. 

The potential of HMX to cause reproductive and developmental effects has not been well investigated 

in animals. In addition, the toxicokinetic data for HMX are very limited. A limited number of in 

vitro studies report that HMX is not mutagenic. However, other genotoxic end points have not been 

studied. 

Minimal Risk Levels for HMX 

Inhalation 

No studies were located regarding adverse health effects in humans or animals after inhalation 

exposure to HMX that provide quantitative information regarding exposure levels. Therefore, no 

inhalation MRLs were derived for HMX. 

Oral 

•	 An MRL of 0.1 mg/kg/day has been derived for acute oral exposure to HMX. This MRL is 

based on a LOAEL of 100 mg/kg/day for neurological effects (hyperkinesia) in mice exposed to 

HMX in the diet for 14 days (Army 1985d). A NOAEL was not identified in this study. The 

LOAEL value of 100 mg/kg/day for hyperkinesia in mice was divided by an uncertainty factor of 
HMX 38 

2. HEALTH EFFECTS 

1,000 (10 for use of a LOAEL, 10 for extrapolation from animals to humans, and 10 for human 

variability). Other studies in animals support the contention that the central nervous system is a 

target for HMX after acute oral exposure (Army 1985e, 1985h). Uncertainty in the acute oral 

MRL arises from the fact that serious neurological effects (convulsions) were observed in rabbits 

administered a single dose of 50 mg/kg HMX by gavage (Army 1985h). While this study 

suggests that rabbits may be the most sensitive species, it has a number of limitations that detract 

from the confidence in the findings, including lack of a control group and the small number of 

animals tested (two animals per exposure group). In addition, gavage administration of HMX 

may have contributed to the apparent greater susceptibility of the rabbits as a result of a bolus 

effect. Nevertheless, if the neurological effects observed in rabbits represent true manifestations 

of HMX toxicity, the current acute oral MRL of 0.1 may not be protective of neurological 

effects. ATSDR recognizes this uncertainty, but maintains greater confidence in the results of 

the mouse study (Army 1985d) than in the rabbit study (Army 1985h). It is possible that rabbits 

are more sensitive to the effects of HMX than other species, but based on current information, 

this conclusion cannot be made with certainty. Further study into this possibility is warranted. 

An MRL of 0.05 mg/kg/day has been derived for intermediate duration oral exposure to HMX. 

This MRL is based on a NOAEL of 50 mg/kg/day for hepatic effects in rats exposed to HMX in 

the diet for 13 weeks (Army 1985c). The NOAEL value was divided by an uncertainty factor of 

100 (10 for extrapolation from animals to humans and 10 for human variability) and by a 

modifying factor of 10 for use of a “limited database” and of data indicating that mice may be 

more sensitive than rats. In this study, doses of 150 mg/kg/day HMX produced enlarged centrilobular 

cells with dark cytoplasm in the livers of exposed rats. These changes were relatively 

mild and may represent an adaptive response of the liver rather than a toxic response. However, 

given that the borderline between adaptive physiology and toxicity is not always well defined, it 

is best to consider these changes as a less serious adverse effect. Higher doses of 

1,500 mg/kg/day (females) and 4,000 mg/kg/day (males) produced significant elevations in the 

serum alkaline phosphatase levels in rats. Support for the MRL comes from a study that 

reported no evidence of systemic toxicity in mice maintained on diets providing 

90-750 mg/kg/day for 13 weeks (Army 1985b). However, mortality was greater than 50% in 

mice exposed to 200-250 mg/kg/day (Army 1985b), suggesting that mice may be more sensitive 

than rats to the lethal effects of HMX. 
HMX 39 

2. HEALTH EFFECTS 

No studies were located regarding the adverse health effects of HMX after chronic oral exposures. 

Death. Data regarding the lethal effects of HMX are limited to studies in animals exposed by oral, 

dermal, and parenteral routes. Deaths have been observed in rats, mice, guinea pigs, and rabbits 

following acute exposure to 50-8,054 mg/kg by the oral route (Army 1985d, 1985e, 1985h), 

634-719 mg/kg by the dermal route (Army 1985h), and l0-38 mg/kg HMX by the parenteral route 

(Army 1974, 1985h). Deaths were also noted in animals following intermediate-duration exposure to 

200-250 mg/kg/day HMX by the oral route (Army 1985b) and 165 mg/kg/day by the dermal route 

(Army 1974). 

The lethal dose of HMX appears to depend greatly on the route of exposure and to some extent on the 

species and sex of the animal exposed. The LD50 values for HMX in rats and mice following 

intravenous exposure were 170-220-fold and 60-110 fold lower than their respective oral LD,, values 

(Army 1974, 1985h), suggesting that HMX is not well absorbed in the gastrointestinal tract. Rabbits 

appeared to be more sensitive to the lethal effects of HMX than other species following oral, dermal, 

and intravenous exposures (Army 1985h). Sex differences were also observed. In most cases, lethal 

doses tended to be slightly lower for male animals than female animals (Army 1985h); however, these 

differences may not be significant. 

Although there have been no reports of human fatalities following exposure to HMX, the animal data 

suggest that oral and dermal exposure to HMX at sufficient doses can be lethal. 

Systemic Effects 

Respiratory Effects. Data regarding the respiratory effects of HMX are limited to a few studies in 

animals exposed by the oral and dermal routes. Respiratory effects (“reddening” of the lungs, 

congestion, white nodules) have been observed in rats, mice, and/or rabbits acutely exposed to 

50-5,447 mg/kg HMX by the oral route and in rabbits acutely exposed to 168 mg/kg HMX by the 

dermal route (Army 1985h). It is not known if this discoloration is the result of irritation in the lung; 

therefore the significance of these observations is uncertain. Other studies have reported no gross or 

histopathological lesions in the lungs of mice orally exposed to 90 mg/kg/day HMX (Army 1985b) or 

in rabbits dermally exposed to 165 mg/kg/day HMX for intermediate durations (Army 1974). 
HMX 40 

2. HEALTH EFFECTS 

Although the data are limited, they suggest that respiratory effects are not of primary concern for 

humans exposed dermally or orally to HMX. 

Cardiovascular Effects. Several animal studies have reported no significant effect on the 

cardiovascular system following oral exposure to 90-5,000 mg/kg/day HMX (Army 1985b, 1985d) and 

dermal exposure to 165-480 mg/kg/day HMX (Army 1974). These studies suggest that cardiovascular 

effects are not of concern to humans exposed to HMX by oral and dermal routes. However, 

intravenous injection of a single dose of 1.55 mg/kg HMX or more produced cardiovascular collapse 

in beagle dogs (Army 1974). Since HMX is known to be poorly absorbed in the gastrointestinal tract, 

it is possible that following oral and dermal exposure, the amount of HMX absorbed into the body is 

generally not sufficient to produce cardiovascular effects but that large absorbed doses of HMX could 

adversely affect the cardiovascular system of humans; however, this is not certain. 

Gastrointestinal Effects. Data regarding the gastrointestinal effects of HMX are limited to studies in 

animals after oral exposure. Although large doses of HMX (1,626-5,447 mg/kg) result in the presence 

of a white fluid in the gastrointestinal tract of exposed animals (Army 1985h), lower doses of HMX 

(90 mg/kg/day) do not result in the formation of histopathological lesions (Army 1985b). However, 

the white fluid was not analyzed; therefore its significance is uncertain. The data, although limited, 

suggest that gastrointestinal effects are not of concern for humans exposed to HMX by the oral route. 

Hematological Effects. No evidence of any hematological effects were observed in 24 male munitions 

workers exposed to an undetermined concentration of HMX in workplace air (Hathaway and Buck 

1977). A single study in animals reported hematological effects (decreased hemoglobin and packed 

cell volume, increased methemoglobin) in rats exposed to 1,500 mg/kg/day for 13 weeks (Army 

1985c). Other studies have not observed hematological effects in rats and mice exposed to 

620-750 mg/kg/day HMX by the oral route (Army 1985b, 1985c) or in rabbits exposed to 165 mg/kg 

HMX by the dermal route (Army 1974). The data suggest that hematological effects may be of 

concern in humans exposed to large doses of HMX. 

Musculoskeletal Effects. Data regarding the musculoskeletal effects of HMX are limited to studies in 

animals exposed by the oral and dermal route. Gross or histopathological lesions of the bones and 

skeletal muscle were not observed in mice exposed orally to 90 mg/kg/day HMX (Army 1985b) or in 
HMX 41 

2. HEALTH EFFECTS 

rabbits exposed dermally to 165 mg/kg/day for intermediate durations (Army 1974). The data suggest 

that musculoskeletal effects are not of concern for humans orally or dermally exposed to HMX. 

Hepatic Effects. No evidence of hepatotoxicity was noted in 24 male munitions workers exposed to 

an undetermined concentration of HMX (Hathaway and Buck 1977). Several studies have reported 

hepatic effects in laboratory animals following oral exposure to 150-8,504 mg/kg/day HMX (Army 

1985c, 1985d, 1985e) or dermal exposure to 372 mg/kg HMX (Army 1985h). Hepatic effects were 

relatively mild (hepatocellular hyperplasia, cytoplasmic eosinophilia, pale nuclei, dark cytoplasm, 

congestion, mottled appearance) at the lower end of the effective dose range and may represent an 

adaptive response. However, the effects were more serious (centrilobular degeneration) at the upper 

end of the dose range. Other animal studies did not report any significant effects on the liver 

following oral exposure to 50-90 mg/kg/day HMX (Army 1985b, 1985c) or dermal exposure to 

165-168 mg/kg/day (Army 1974, 1985h). However, histopathological examinations were not 

performed in female mice exposed to doses greater than 90 mg/kg/day or in male mice exposed to 

doses greater than 75 mg/kg/day. An intermediate MRL of 0.05 mg/kg/day was derived for HMX 

based on a NOAEL of 50 mg/kg/day for hepatic effects in rats (Army 1985c). The data from animal 

studies suggests that hepatic effects may be of concern in humans exposed to moderate-to-high doses 

of HMX at the workplace or at hazardous waste sites. 

Renal Effects. No evidence of renal toxicity was observed in 24 male munitions workers exposed to 

an undetermined concentration of HMX in workplace air (Hathaway and Buck 1977). Renal effects 

(focal tubular atrophy, dilatation, congestion, pale and/or mottled appearance) were noted in animals 

after oral doses of 270-3,632 mg/kg/day HMX (Army 1985c, 1985e, 1985h) or dermal doses of 

168 mg/kg HMX (Army 1985h). Elevated blood urea nitrogen levels were noted in male and female 

rats following oral doses of 1,500-4,000 mg/kg/day HMX (Army 1985c). Other studies did not report 

renal effects in animals exposed to 90-115 mg/kg/day HMX (Army 1985b, 1985c) by the oral route or 

165 mg/kg/day HMX by the dermal route (Army 1974). The animal data suggest that renal effects 

may be of concern in humans exposed to moderate-to-high doses (i.e., doses well above-the MRL) of 

HMX by the oral and dermal routes. 

Dermal Effects. Data regarding the dermal effects of HMX are limited to studies in animals exposed 

by the oral and dermal routes. Repeated oral doses of 90-4,000mg/kg/day produced no effects on the 

skin of exposed animals (Army 1985b, 1985c). However, direct exposure of the skin to doses of 
HMX 42 

2. HEALTH EFFECTS 

16.5-1,000 mg/kg/day HMX often produces mild irritation at the site of application (Army 1974, 

1985h). The data from animal studies suggest that humans exposed to HMX by the dermal route may 

be at risk for dermal effects, but that these effects are relatively mild. 

Ocular Effects. Data regarding the ocular effects of HMX are limited. Direct exposure of the eyes of 

guinea pigs and rabbits to doses of 16.5-1,000 mg/kg/day HMX produced mild irritation at the site of 

application (Army 1974, 1985h). 

Body Weight Effects. Decreased body weight gain and food intake occurred in rats following doses of 

2370 mg/kg/day in the diet (Army 1985c, 1985e), but not in mice following doses of 750 mg/kg/day 

(Army 1985b). These data are too limited to make firm conclusions regarding body weight effects in 

humans exposed to HMX. 

Immunological and Lymphoreticular Effects. No evidence of lupus erythematosus was 

observed in a group of 558 male and female munitions workers exposed to an unspecified 

concentration of explosives, including HMX, in workplace air (Hathaway and Buck 1977). Changes in 

the thymus and spleen (decreased organ weight or lymphocyte depletion) were noted in laboratory 

animals orally exposed to 50-1,280 mg/kg/day (Army 1985d, 1985e). Spleen enlargement was noted 

in rabbits following a single dermal dose of 168 mg/kg HMX (Army 1985h). However, it is not 

known if immune function was affected in these animals. Dermal exposure to 357 mg/kg HMX did 

not produce an allergic reaction in guinea pigs exposed previously to HMX (Army 1985h). The 

animal data are too limited to make firm conclusions, but suggest that immunological effects may be 

of concern for humans exposed to HMX. 

Neurological Effects. Several studies have reported neurological effects in animals after acute oral, 

dermal, and intravenous exposure to HMX. Hyperkinesia, hypokinesia, convulsions, mydriasis, 

congestion, and/or hemorrhaging of the brain were noted in laboratory animals following oral doses of 

50-8,504 mg/kg/day HMX (Army 1985d, 1985e, 1985h) and dermal application of 168 mg/kg HMX 

(Army 198511). In addition, intravenous doses of l-28.9 mg/kg HMX have produced similar effects 

(convulsions, hyperkinesia, paralysis, coma) in rats, mice, rabbits, guinea pigs, and dogs (Army 1974, 

1985h). Rabbits appeared to be the most sensitive to the neurological effects of HMX following oral 

and dermal exposures. However, as discussed previously, there are several deficiencies in the Army 

1985h study that preclude a definitive conclusion. In this regard, gavage administration of the HMX 
HMX 43 

2. HEALTH EFFECTS 

may have contributed to the apparent greater susceptibility of the rabbits as a result of a bolus effect. 

However, very little difference was observed between species following intravenous exposures. The 

data suggest that species differences in absorption and/or first-pass metabolism may underlie the 

species differences observed for the adverse health effects of HMX. An acute oral MRL of 

0.1 mg/kg/day was derived for HMX based on a LOAEL of 100 mg/kg/day for neurological effects 

(hyperkinesia) in mice exposed to HMX in the diet for 14 days (Army 1985d). The data from animal 

studies suggest that the central nervous system may be a target for HMX toxicity and that neurological 

effects may be of concern for humans exposed to HMX either occupationally or at hazardous waste 

sites. 

Reproductive Effects. Data regarding the reproductive effects of HMX are limited to studies in 

animals exposed by the oral route. Histopathological lesions were not observed in ovaries or testes of 

mice exposed to 90 mg/kg/day HMX for 13 weeks (Army 1985b). However, reproductive function 

was not evaluated in this study. The animal data are too limited to make firm conclusions regarding 

the risk of reproductive effects in humans exposed to HMX. 

Developmental Effects. No studies were located regarding developmental effects in humans or 

animals following exposure to HMX. 

Genotoxic Effects. No studies were located regarding genotoxic effects in humans or animals after 

exposure to HMX in vivo. Data regarding the genotoxic effects of HMX are limited to a few in vitro 

studies. The results of these studies are summarized in Table 2-3 and are discussed below. 

Three studies did not detect an increased mutation frequency with HMX in several strains of 

Salmonella typhimurium (TA98, TA100, TA1535, TA1537, TA1538), both in the presence and 

absence of an activation system (Army 1977c; Tan et al. 1992; Whong et al. 1980). Chlorination or 

composting had no effect on the mutagenicity of HMX (Army 1977c; Tan et al. 1992). Waste waters 

that contained HMX from an ammunition plant did not produce a significant increase ofmutation 

frequency in several strains of Salmonella typhimurium (Army 1977a). The authors generally 

concluded that HMX was not mutagenic under the conditions of these assays. In addition, the 

frequency of mitotic recombination was not significantly increased in Saccharomyces cerevisiae (Army 

1977c). Although the data are limited in the number of end points investigated, they suggest that 

HMX is not genotoxic. 

HMX 45 

2. HEALTH EFFECTS 

Cancer. There is some indirect evidence that suggests HMX may be carcinogenic. RDX, another 

explosive polynitramine that is similar in structure to HMX, is known to produce hepatocellular 

adenomas and carcinomas in female mice (IRIS 1995). In addition, some of the potential metabolites 

of HMX (hydrazines, nitrosamines) are carcinogenic. However, the carcinogenic effects of HMX have 

not been studied in humans or animals. Based on the lack of appropriate cancer bioassays and 

epidemiological studies, EPA has determined that HMX is not classifiable as to its human 

carcinogenicity (Group D) (IRIS 1995). 

2.6 BIOMARKERS OF EXPOSURE AND EFFECT 

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They 

have been classified as markers of exposure, markers of effect, and markers of susceptibility 

(NAS/NRC 1989). 

Due to a nascent understanding of the use and interpretation of biomarkers, implementation of 

biomarkers as tools of exposure in the general population is very limited. A biomarker of exposure is 

a xenobiotic substance or its metabolite(s), or the product of an interaction between a xenobiotic agent 

and some target molecule(s) or cell(s) that is measured within a compartment of an organism 

(NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself or 

substance-specific metabolites in readily obtainable body fluid(s) or excreta. However, several factors 

can confound the use and interpretation of biomarkers of exposure. The body burden of a substance 

may be the result of exposures from more than one source. The substance being measured may be a 

metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from 

exposure to several different aromatic compounds). Depending on the properties of the substance 

(e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the 

substance and all of its metabolites may have left the body by the time samples can be taken. It may 

be difficult to identify individuals exposed to hazardous substances that are commonly found in body 

tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of 

exposure to HMX are discussed in Section 2.6.1. 

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within 

an organism that, depending on magnitude, can be recognized as an established or potential health 
HMX 46 

2. HEALTH EFFECTS 

impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals 

of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital 

epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or 

decreased lung capacity. Note that these markers are not often substance specific. They also may not 

be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of 

effects caused by HMX are discussed in Section 2.6.2. 

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s 

ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an 

intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed 

dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of 

susceptibility exist, they are discussed in Section 2.8, Populations That Are Unusually Susceptible. 

2.6.1 Biomarkers Used to Identify or Quantify Exposure to HMX 

Studies in animals show that biological samples (plasma, tissues, urine, feces) can be analyzed for 

HMX content (Army 1958g, 1986). These studies suggest HMX is poorly absorbed by the oral route 

(Army 1986), and therefore levels of HMX in plasma, tissues, and urine are likely to be very low. 

Higher levels are more likely to be detected in the feces following oral exposure, but only for the first 

l-2 days after exposure ceases. Since the metabolites of HMX have not been well characterized, they 

cannot be used as biomarkers of exposure for HMX. 

2.6.2 Biomarkers Used to Characterize Effects Caused by HMX 

Studies in animals indicate that the critical effects of HMX are on the liver, the kidney, and the central 

nervous system (see Section 2.2) (Army 1985d, 1985h). Measurement of enzymes in the blood that 

are indicative of liver damage (alkaline phosphatase, lactate dehydrogenase, serum glutamic 

oxaloacetic transaminase, serum glutamic pyruvic transaminase), measurement of blood meal nitrogen 

levels to assess renal damage, or monitoring electroencephalogram readings may serve as biomarkers 

of effect for HMX. However, these biomarkers are by no means specific for HMX, as many 

exogenous compounds and endogenous diseases are capable of producing similar effects. 
HMX 47 

2. HEALTH EFFECTS 

2.7 INTERACTIONS WITH OTHER SUBSTANCES 

No studies were located regarding interactions with other substances in humans or animals after 

exposure to HMX. 

2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 

A susceptible population will exhibit a different or enhanced response to HMX than will most persons 

exposed to the same level of HMX in the environment. Reasons include genetic make-up, 

developmental stage, age, health and nutritional status (including dietary habits that may increase 

susceptibility, such as inconsistent diets or nutritional deficiencies), and substance exposure history 

(including smoking). These parameters may result in decreased function of the detoxification and 

excretory processes (mainly hepatic, renal, and respiratory) or the pre-existing compromised function 

of target organs (including effects or clearance rates and any resulting end-product metabolites). For 

these reasons we expect the elderly with declining organ function and the youngest of the population 

with immature and developing organs will generally be more vulnerable to toxic substances than 

healthy adults. Populations who are at greater risk due to their unusually high exposure are discussed 

in Section 5.6, Populations With Potentially High Exposure. 

No studies were located regarding susceptible populations in humans or animals exposed to HMX. 

Since studies in animals indicate that the liver, kidney, and central nervous system are the most 

sensitive targets of HMX toxicity, people with liver damage (cirrhosis, hepatitis), kidney damage, or 

neurological disorders (Parkinson’s disease, epilepsy) may be more susceptible to the effects of HMX. 

Since HMX appears to be poorly absorbed in the gastrointestinal tract (Army 1986), persons with 

increased absorption capacity, either due to stomach ulcers, open wounds on the skin, or for some 

other reason, may also be more susceptible to the effects of HMX. However, these possibilities have 

not been studied. 
HMX 48 

2. HEALTH EFFECTS 

2.9 METHODS FOR REDUCING TOXIC EFFECTS 

This section describes clinical practice and research concerning methods for reducing toxic effects of 

exposure to HMX. However, because some of the treatments discussed may be experimental and 

unproven, this section should not be used as a guide for treatment of exposures to HMX. When 

specific exposures have occurred, poison control centers and medical toxicologists should be consulted 

for medical advice. 

2.9.1 Reducing Peak Absorption Following Exposure 

No studies were located for reducing absorption in humans or animals exposed to HMX. However, 

standard methods exist to reduce the absorption of chemicals such as HMX following oral exposure, 

including gastrointestinal lavage, induced emesis, and cathartics (Ellenhom and Barceloux 1988). 

However, since studies in animals suggest HMX is not well absorbed in the gastrointestinal tract 

(Army 1986), these methods may not have a significant effect. For situations in which a larger 

fraction of HMX may be absorbed (for example, when in solution, or at low doses) activated charcoal 

may be useful in slowing absorption. Oils have been contraindicated for use as a lavage or cathartic, 

because oils may increase the gastrointestinal absorption of HMX (Ellenhom and Barceloux 1988). 

Common methods for reducing dermal absorption of HMX include removing contaminated clothes and 

washing contacted skin with soap and water (Ellenhom and Barceloux 1988). Oils have been 

contraindicated for cleaning the skin, since oils may increase the dermal absorption of HMX 

(Ellenhom and Barceloux 1988). Following eye contact with HMX, it has been suggested that contact 

lenses (if present) be removed and eyes flushed with copious amounts of water (Ellenhorn and 

Barceloux 1988). 

2.9.2 Reducing Body Burden 

No studies were located regarding methods to reduce body burden in humans or animals after exposure 

to HMX. Activated charcoal, given in serial doses, has been suggested to minimize enterohepatic 

recirculation of toxic chemicals. Unfortunately, the enterohepatic recirculation of HMX has not been 

investigated, therefore it is not known whether or not serial doses of activated charcoal would have a 

significant effect. 
HMX 49 

2. HEALTH EFFECTS 

2.9.3 Interfering with the Mechanism of Action for Toxic Effects 

Although the mechanism of action of HMX is not known, this mechanism may involve the formation 

of nitrite or hydrazines during the metabolism of HMX. Efforts to inhibit the enzyme systems 

responsible for the formation of these intermediates could interfere with the mechanism of action for 

the toxic effects of HMX. Methylene blue and pyridoxine have been suggested for interfering with the 

mechanisms of action for nitrite and hydrazines, respectively (Ellenhorn and Barceloux 1988). If the 

formation of nitrite or hydrazines is involved in the mechanism of action for HMX, then treatment 

with methylene blue and pyridoxine may also be useful in treating individuals exposed to HMX. It 

should be noted that treatment with methylene blue or pyridoxine is not without risk, as these agents 

are capable of producing adverse effects themselves. 

2.10 ADEQUACY OF THE DATABASE 

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 

the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 

adequate information on the health effects of HMX is available. Where adequate information is not 

available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure 

the initiation of a program of research designed to determine the health effects (and techniques for 

developing methods to determine such health effects) of HMX. 

The following categories of possible data needs have been identified by a joint team of scientists from 

ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 

reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 

that all data needs discussed in this section must be filled. In the future, the identified data needs will 

be evaluated and prioritized, and a substance-specific research agenda will be proposed. 

2.10.1 Existing Information on Health Effects of HMX -. 

The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 

HMX are summarized in Figure 2-2. The purpose of this figure is to illustrate the existing information 

concerning the health effects of HMX. Each dot in the figure indicates that one or more studies 

provide information associated with that particular effect. The dot does not necessarily imply anything 

HMX 51 

2. HEALTH EFFECTS 

about the quality of the study or studies, nor should missing information in this figure be interpreted as 

a “data need.” A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific 

Data Needs Related to Toxicological Profiles (ATSDR 1989), is substance-specific information 

necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap 

more broadly as any substance-specific information missing from the scientific literature. 

As shown in Figure 2-2, information in humans is limited to a single study that investigated systemic 

and immunologic effects after chronic inhalation exposure to HMX. 

2.10.2 Identification of Data Needs 

Acute-Duration Exposure. No human data were located regarding acute-duration exposure to 

HMX by any route. In addition, no animal data were located regarding acute inhalation exposure to 

HMX. Studies in several animal species suggest that the central nervous system may be a target of 

HMX toxicity after oral (Army 1985d, 1985e, 1985h), dermal (Army 1985h), and parenteral (Army 

1974, 1985h) routes of exposure. The data are sufficient to support the derivation of an acute oral 

MRL of 0.1 mg/kg/day. This MRL is based on a LOAEL of 100 mg/kg/day for neurological effects 

in mice (Army 1985d). Uncertainty in the acute oral MRL arises from the fact that serious 

neurological effects (convulsions) were observed in rabbits administered a single dose of 50 mg/kg 

HMX by gavage (Army 1985h). Additional acute studies in animals exposed to HMX by all three 

routes are needed to better define the threshold dose at which neurological effects occur. Such studies 

may be useful in predicting the risk of neurological effects in humans acutely exposed to HMX by 

similar routes, either occupationally or at hazardous waste sites. Case studies of accidental human 

exposure to HMX may serve to indicate whether or not the effects observed in animals are also 

observed in humans and may be useful in selecting the most appropriate animal model for HMX 

toxicity. 

Intermediate-Duration Exposure. No human data were located regarding intermediate-duration 

exposure to HMX by any route. Studies in animals are limited, but suggest that the liver, kidney, and 

skin are targets of HMX toxicity following oral and dermal exposures (Army 1974, 1985b). The data 

are sufficient to support the derivation of an intermediate oral MRL of 0.05 mg/kg/day. This MRL is 

based on a NOAEL of 50 mg/kg/day for hepatic effects observed in rats (Army 1985c). Additional 

animal studies (particularly those in mice and rabbits) that confirm the critical effects of HMX 
HMX 52 

2. HEALTH EFFECTS 

following inhalation, oral, and dermal exposure and better define the threshold dose at which these 

effects occur would be useful in predicting the risk of adverse health effects in humans exposed at the 

workplace or at hazardous waste sites by similar routes. Epidemiological studies of humans 

occupationally exposed to HMX that quantitate exposure may serve to indicate whether the effects 

observed in animals are also observed in humans. 

Chronic-Duration Exposure and Cancer. In a single human study, no signs of hematological, 

hepatic, kidney, or immunological effects were reported in munitions workers exposed to an 

unspecified concentration of HMX in air (Hathaway and Buck 1977). No other studies were located 

regarding adverse effects in humans after exposure to HMX by any route. Additional epidemiological 

studies which quantitate human exposure and employ larger study populations may be useful in 

defining the threshold dose for HMX-related effects. No studies were located regarding adverse health 

effects in animals following exposure to HMX by any route. Studies in animals that investigate the 

adverse health effects associated with chronic exposure to HMX by all routes would be useful in 

predicting the risk of adverse health effects in humans exposed at the workplace or hazardous waste 

sites for similar durations. 

There are no human or animal data regarding any potential carcinogenic effects of HMX. 

Epidemiological studies and chronic studies in animals exposed by all three routes would be useful in 

determining if humans exposed to HMX in the workplace or at hazardous waste sites are at increased 

risk for developing cancer. 

Genotoxicity. No human or animal data were located regarding the genotoxicity of HMX following 

exposure by any route. A limited number of in vitro studies indicate that HMX does not increase the 

frequency of mutations or mitotic recombinations (Army 1977c; Tan et al. 1992; Whong et al. 1980). 

Studies in humans occupationally exposed to HMX and in animals exposed to HMX by all three 

exposure routes may confirm the findings of in vitro studies. Additional in vitro studies which 

evaluate other end points of genotoxicity (for example, sister chromatid exchange and chromosomal 

aberrations) would be useful in providing a complete profile of the genotoxicity of HMX. 
HMX 53 

2. HEALTH EFFECTS 

Reproductive Toxicity. No human data were located regarding the reproductive effects of HMX. 

Limited data from animal studies indicate that HMX does not produce histopathological lesions of the 

ovaries or testes following oral exposure (Army 1985b). Epidemiological studies of male and female 

workers exposed to HMX and additional animal studies that investigate the effects of HMX on 

reproductive function would help determine if reproductive effects are of concern for humans exposed 

to HMX in occupational settings or at hazardous waste sites. 

Developmental Toxicity. No human or animal data were located regarding the developmental 

effects of HMX. Epidemiological studies that investigate infants and children born of parents exposed 

to HMX in the workplace would be useful in determining if developmental effects are of concern for 

humans exposed to HMX occupationally or at hazardous waste sites. Studies in animals exposed to 

HMX by all three exposure route could help define the threshold dose at which potential 

developmental effects may occur. 

Immunotoxicity. A single human study reported no evidence of lupus erythematosus in munitions 

workers, some of whom were exposed to an unspecified concentration of HMX in workplace air 

(Hathaway and Buck 1977). Effects were noted in the thymus and spleen of animals exposed to HMX 

by the oral and dermal routes (Army 1985a, 1985d, 1985h), but the effects on immunological function 

were not determined. Additional studies of humans occupationally exposed to HMX that investigate 

other immunological parameters, and additional studies in animals exposed via all routes which 

investigate the effects of HMX on immunological function would help determine if immunological 

effects are of concern for humans exposed to HMX. 

Neurotoxicity. No human data were located regarding the neurological effects of HMX. Studies in 

animals have reported neurological effects (hyperkinesia, hypokinesia, convulsions) following acute 

oral (Army 1985d, 1985e, 1985h), dermal (Army 1985h), and parenteral (Army 1974, 198511) 

exposures to HMX. Although one study suggests that rabbits may be more sensitive than other 

species following oral or dermal exposure to HMX, there are numerous limitations in this rabbit study. 

These limitations include the lack of a control group, a small number of animals tested, and the possibility 

that gavage administration may have contributed to the apparently greater susceptibility of the 

rabbit as result of a bolus effect. Case studies of humans which report neurological effects following 

accidental exposure to HMX would determine if the effects observed in animals are also observed in 

humans. Additional animal studies, particularly those in rabbits, that better define the threshold dose 
 

HMX 54 

2. HEALTH EFFECTS 

for neurological effects for all three exposure routes would be helpful in predicting the potential for 

neurological effects in humans exposed to HMX in the workplace or at hazardous waste sites. 

Epidemiological and Human Dosimetry Studies. A single human study reported no evidence 

of adverse health effects in munitions workers exposed to an unspecified concentration of HMX in 

workplace air (Hathaway and Buck 1977). Additional studies of munitions workers exposed to HMX 

which employ larger study populations, quantify exposure, and determine the resulting levels of HMX 

or its metabolites in plasma, urine, and feces may be useful in estimating exposure to humans living 

near hazardous waste sites. 

Biomarkers of Exposure and Effect 

Exposure. The levels of HMX have been determined in the plasma, tissues, urine, and feces in 

animals shortly following oral and parenteral exposure to HMX (Army 1985g, 1986). Additional 

studies which identify and quantify the metabolites of HMX in biological samples could lead to the 

development of biomarkers which are also specific to HMX exposures and could be used for future 

medical surveillance. Such efforts could lead to early detection and possible treatment. 

Effect. Measurements can be made for serum enzyme activities (alkaline phosphatase, lactate 

dehydrogenase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase) or for 

brain wave alterations (electroencephalograph) to determine the magnitude of the hepatic and 

neurological effects of HMX. However, these biomarkers are not specific for exposures to HMX. 

Studies which provide insight into the mechanism of action of HMX could lead to the development of 

biomarkers of effect that are specific to HMX. 

Absorption, Distribution, Metabolism, and Excretion. There are no data regarding the 

toxicokinetics of HMX in humans. Studies in animals exposed to HMX by the oral and parenteral 

route suggest that HMX is poorly absorbed from the gastrointestinal tract (Army 1985g,--1986), and 

may preferentially distribute to the lungs, liver, heart, and kidney, and that most of an absorbed dose 

of HMX is excreted in the urine (Army 1986). The data regarding the metabolism of HMX are 

extremely limited, and data regarding the mechanism of action of HMX are purely speculative. 

Studies in animals which investigate the toxicokinetics of HMX following inhalation and dermal 

exposure would be useful in predicting the risk of adverse health effects following exposure to HMX 
HMX 55 

2. HEALTH EFFECTS 

by these routes. Studies which provide insight into the metabolism and mechanism of action of HMX 

could lead to the development of sensitive biomarkers and effective treatments for the toxic effects of 

HMX. 

Studies that investigate the absorption, distribution, metabolism, and excretion of HMX in animals 

(particularly rabbits) following single and repeated exposures to HMX for a wide range of doses by all 

three routes may provide important information regarding the time- and dose-dependency of the 

toxicokinetics of HMX. 

Comparative Toxicokinetics. There are no human data regarding the toxicokinetics of HMX. 

Animal studies regarding the toxicokinetics of HMX are too limited to indicate any species 

differences. However, species differences have been observed for the toxic effects of HMX (Army 

1985h). Additional animal studies which investigate potential species differences in absorption, 

distribution, metabolism, and/or excretion of HMX would be useful in understanding the mechanism 

underlying the species differences in sensitivity to the adverse health effects of HMX. Studies of 

humans following occupational or accidental exposure to HMX would be useful in determining which 

animal species are good models. In vitro studies which investigate the metabolism of HMX using 

microsomal fractions from human and animal tissues may indicate important species differences and/or 

similarities across species. 

Methods for Reducing Toxic Effects. There are no data regarding the reduction of toxic effects 

of HMX in humans or animals. Although standard methods exist for reducing the absorption of 

chemicals such as HMX following oral or dermal exposure, studies which investigate the mechanism 

by which HMX is absorbed could lead to the development of methods which are specific for exposure 

to HMX. Data regarding the toxicokinetics of HMX are limited. Additional studies which better 

define the metabolism and mechanism of action of HMX could lead to the development of methods 

for reducing body burden and interfering with the mechanism of action of HMX. 

2.10.3 On-going Studies 

No information was located regarding on-going studies on HMX. 

HMX 57 

3. CHEMICAL AND PHYSICAL INFORMATION 

3.1 CHEMICAL IDENTITY 

Table 3-l lists common synonyms, trade names, and other pertinent identification information for 

HMX. 

3.2 PHYSICAL AND CHEMICAL PROPERTIES
 

Table 3-2 lists important physical and chemical properties of HMX.
 



HMX 61 

4. PRODUCTION, IMPORT, USE, AND DISPOSAL 

4.1 PRODUCTION 

HMX is produced by the nitration of hexamine with ammonium nitrate and nitric acid in an acetic 

acid/acetic anhydride solvent at 44°C. The raw materials are mixed in a two-step process and the 

product is purified by recrystallization. This is a modification of the Bachmann Process used to 

produce RDX, another explosive. The yield of HMX is about 55-60%, with RDX as an impurity. 

RDX produced by the Bachmann Process usually contains about 8-12% HMX as an acceptable byproduct 

(Army 1984a, 1989; EPA 1986, 1988). 

HMX is currently produced at only one facility in the United States, the Holston Army Ammunition 

Plant in Kingsport, Tennessee. Estimated production volume of HMX was about 30 million pounds 

annually between 1969 and 1971. No estimates of current production volume were located, but it is 

estimated that its use is increasing (Army 1984a, 1989; EPA 1986). 

Processing may occur at load, assemble, and pack (LAP) facilities operated by the military (Army 

1984a; EPA 1988). There were 10 facilities engaged in LAP operations in the United States in 1976 

(Army 1984a). 

4.2 IMPORT/EXPORT 

No information was located regarding import or export of HMX in the United States. Export of this 

chemical is regulated by the U.S. State Department (see Table 7-l) (Department of State 1992). 

4.3 USE 

HMX is used to implode fissionable material in nuclear devices to achieve critical mass and as a 

component of plastic-bonded explosives, solid fuel rocket propellants, and as burster chargers in 

military munitions (EPA 1988). The use of HMX as a propellant and in maximum-performance 

explosives is increasing (Army 1989). Data on quantities of HMX currently consumed for these uses 

were not located. 
HMX 62 

4. PRODUCTION, IMPORT, USE, AND DISPOSAL 

4.4 DISPOSAL 

Wastes from explosive manufacturing processes are classified as hazardous wastes by EPA. 

Generators of these wastes must conform to EPA regulations for treatment, storage, and disposal (see 

Chapter 7). The waste water treatment sludges from processing of explosives are listed as hazardous 

wastes by EPA based only on reactivity (EPA 1986). Waste water treatment may involve filtering 

through activated charcoal, photolytic degradation, and biodegradation (EPA 1988). Rotary kiln or 

fluidized bed incineration methods are acceptable disposal methods for HMX-containing wastes. 

At the Holston facility, waste waters are generated from the manufacturing areas and piped to an 

industrial water treatment plant on site. Following neutralization and nutrient addition, sludge is 

aerobically digested and dewatered. It was estimated that the facility generates a maximum of 

3,800 tons (7.6 million pounds) of treated, dewatered sludge annually. Based on demonstration by 

Holston that this sludge is nonhazardous, the EPA proposed granting a petition to exclude the sludge 

from hazardous waste control (EPA 1986). HMX is not listed on the Toxics Release Inventory (TRI) 

database, because it is not a chemical for which companies are required to report discharges to 

environmental media. 
HMX 63 

5. POTENTIAL FOR HUMAN EXPOSURE 

5.1 OVERVIEW 

HMX is a high explosive chemical which does not occur naturally. Most of the HMX entering 

environmental media is from discharge of waste waters from manufacture and processing of the 

chemical into aquatic environments. Treatment and disposal of other HMX-containing wastes also 

contributes to the environmental concentrations of this chemical. 

HMX is persistent in the environment, with little transport from water to other media. Volatilization, 

sorption, and bioconcentration are not expected to be important. The primary transformation process 

is photolysis, with a half-life of about 17 days in river water. Biodegradation may occur in waste 

water and in water enriched with nutrients under aerobic and anaerobic conditions, but is not expected 

to be significant in ambient waters. 

Exposure of the general population to HMX, if it occurs at all, is expected to be low. If exposure 

does occur, it is most likely to arise from drinking or showering with HMX-contaminated water at or 

near processing facilities or hazardous waste sites. 

HMX has been identified in at least 10 of the 1,416 hazardous waste sites that have been proposed for 

inclusion on the EPA National Priorities List (NPL) (HazDat 1995). However, the number of sites 

evaluated for HMX is not known. The frequency of these sites within the United States can be seen 

in Figure 5-l. 

5.2 RELEASES TO THE ENVIRONMENT 

5.2.1 Air 

Although no data were located, it is unlikely that substantial quantities of HMX are released to air. 

The chemical is not volatile, but, based on detection of RDX on particulate emissions (Army 1984a), 

may adsorb to particulates generated during burning of HMX-containing materials. Concentrations of 

HMX 65 

5. POTENTIAL FOR HUMAN EXPOSURE 

HMX released to air in this manner are expected to be low. HMX is not listed on the TRI database, 

so estimates of environmental release of this chemical are not available from this source. 

5.2.2 Water 

Releases of HMX to surface water may occur from discharge of waste waters from production and 

processing of the chemical. In the past, reported concentrations of HMX in manufacturing effluents 

ranged from 0.09 to 3.59 mg/L (Army 1983, 1984a). Based on these concentrations, it was estimated 

that the Holston facility discharged about 45-123 pounds per day of HMX into the Holston River 

(Army 1984a). Waste waters from LAP operations such as washdown, explosive melting, and reject 

warhead steam cleaning may also contain HMX (EPA 1988). However, based on data for RDX, waste 

water treatment may reduce HMX concentrations by one to two orders of magnitude (Army 1984a). 

No information on the current status of waste water treatment at facilities generating waste waters 

containing HMX was located. 

5.2.3 Soil 

HMX may be released to soil by industrial sources and from hazardous waste sites at which this 

chemical has been detected. Releases may be via deposition of airborne particles from manufacture or 

incineration, spills occurring during manufacture, transportation, or storage, or landfilling of explosive 

wastes or explosive-generated incineration ashes (Army 1984a; EPA 1988). No data regarding 

quantities of HMX released to soil by these processes were located. 

5.3 ENVIRONMENTAL FATE 

5.3.1 Transport and Partitioning 

HMX released to water or soil may volatilize into air or sorb onto soil and sediments. However, 

neither volatilization nor sorption are expected to be major removal mechanisms for HMX. The 

volatilization rate constant from aquatic systems was estimated at about 2.4 x 10-4 to 7.2 x 10-4 day-1, 

resulting in a volatilization half-life of about 3,000-1,000 days for HMX (Army 1984a). In aquatic 

environments, adsorption to suspended solids and partitioning to sediments may occur, but is not 
HMX 66 

5. POTENTIAL FOR HUMAN EXPOSURE 

considered a major fate process (EPA 1988). Thus, HMX may be transported for a considerable 

distance in water. 

Based on the calculated soil adsorption factor (log Kocof 0.54), HMX is expected to have high 

mobility in soil. Results of laboratory studies indicate that HMX was present in leachate from various 

types of soils and is likely to migrate into groundwater (Army 1982b, 1984b). However, the extent of 

migration to groundwater is limited by the relatively low solubility of HMX in water (6.63 mg/L) 

(EPA 1988). Therefore, the migration of HMX through soil is expected to be slow, resulting in low 

concentrations in groundwater (EPA 1988). The highest migration rate was reported in coarse, loamy 

soil (Army 1984a). More recently, a study was conducted on the migration of HMX in soil obtained 

from the Milan Army Ammunition Plant in Milan, Tennessee (Checkai et al. 1993). Experiments 

involved leaching soil columns with synthetic rainwater for up to 243 days. HMX, at an average 

concentration of 0.4 mg/L, was detected in the leachate samples. No biodegradation products of HMX 

were detected. HMX had migrated the full soil-core length by 19.5 weeks. 

Atmospheric transport of HMX may occur, based on persistence of munitions compounds in air (Army 

1984a), but no data were located to support this hypothesis. 

No data regarding the bioconcentration potential of HMX were located. Bioaccumulation of HMX is 

not expected to be significant, based on bioconcentration and elimination studies on RDX, an HMX 

analog, in several species (Army 1984a). 

5.3.2 Transformation and Degradation 

5.3.2.1 Air 

No data were located on HMX transformations in the atmosphere. 

5.3.2.2 Water 

HMX is relatively stable in the aquatic environment. Neither hydrolysis nor oxidation of HMX in 

water are expected to be important removal processes (EPA 1988). Direct photolysis is probably the 

primary transformation pathway for HMX in aquatic systems. Photolysis rate constants reported for HMX 
 

67 

5. POTENTIAL FOR HUMAN EXPOSURE 

HMX were 0.19, 0.166, and 0.0099 day

-1 in pure water, Holston River water, and Louisiana Army 

Ammunition Plant (LAAP) lagoon water, respectively (Army 1983). The resulting photolytic halflives 

for HMX were 1.4, 1.7, and 70 days, respectively. The major difference affecting the photolysis 

rate in these laboratory experiments appeared to be light attenuation by ultraviolet absorbing species in 

the lagoon water. The rate did not appear to be affected by co-substrates in solution. The observed 

stable end products of HMX photolysis were nitrate, nitrite, and formaldehyde. Since the nitrate and 

nitrite ions accounted for only 50% of the nitro groups per mole of HMX consumed, the authors 

proposed a photolysis mechanism, summarized in Figure 5-2, which includes dinitrogen oxide, 

ammonia, and formamide as additional end products. Modeling of Holston River and LAAP lagoon 

waters, including such factors as water flow, depth, and seasonal changes in rate constants, indicated 

that the average half-life of HMX would be 17 days in the Holston River and 7,900 days in the LAAP 

lagoon. Dilution served as the primary mechanism for reduction of HMX concentration, with 

photolysis contributing losses of l-5%. The authors concluded that HMX may persist in the Holston 

River for a significant distance (more than 20 km) from the Holston plant. 

Biodegradation does not appear to be significant in ambient waters; however, some studies indicate 

that biodegradation may be an important removal process for HMX in manufacturing effluents and in 

waters containing organic nutrients. Aerobic and anaerobic biotransformation was reported in waste 

water and river water enriched with nutrients. The transformation products included mono- through 

tetra-nitroso derivatives of HMX, which eventually were metabolized to l,l-dimethylhydrazine (Army 

1983). Transformation was not significant in the Holston River water or the LAAP lagoon water. 

The authors postulated that the levels of organisms and nutrients in the water were too low to support 

the biotransformation of HMX (Army 1983). Other studies confirmed the anaerobic, but not aerobic, 

biotransformation of HMX in nutrient broth culture systems inoculated with sewage sludge (Army 

1984d). 

5.3.2.3 Sediment and Soil 

No data were located regarding HMX transformation in soil or sediment. Based on data for RDX and 

HMX transformations in water, microbial degradation does not proceed rapidly and the chemical may 

be persistent in soil and sediments (Army 1984a). 

HMX 69 

5. POTENTIAL FOR HUMAN EXPOSURE 

5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 

5.4.1 Air 

No monitoring data for HMX in ambient air were located. 

5.4.2 Water 

HMX has been detected in groundwater samples at the northern facility boundary of the Milan Army 

Ammunition Plant in Milan, Tennessee (EPA 1994). Concentrations of 0.53-821.0 μg/L HMX were 

detected in monitoring well groundwater samples. HMX has also been detected in surface waters 

receiving effluents from HMX manufacturing and processing facilities. HMX was detected at a 

concentration of 67 μg/L in the Holston River, one mile downstream of the last plant effluent (Army 

1984a). 

5.4.3 Sediment and Soil 

At the Joliet Army Ammunition Plant located in Joliet, Illinois, HMX has been detected in soil 

samples at concentrations of 5-3,054 μg/g (Phillips et al. 1994). HMX, at a concentration of 13 μg/g, 

was detected by high-performance liquid chromatography (HPLC) in soil obtained from the Milan 

Army Ammunition Plant, Milan, Tennessee (Phillips et al. 1993). High levels could be present in 

limited areas as a result of releases from manufacture and processing as well as from waste disposal in 

landfills (Army 1984a). 

5.4.4 Other Environmental Media 

No data were located regarding HMX in foods or other environmental media. 

5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 

Exposure of the general population to HMX is expected to be extremely low, but data are insufficient 

for exposure estimates. The chemical has only been detected in environmental media in the vicinity of 
HMX 70 

5. POTENTIAL FOR HUMAN EXPOSURE 

manufacturing or processing facilities or hazardous waste sites. If exposure of the general population 

to HMX occurred, water would be the most likely source (Army 1989). 

Workers in military facilities manufacturing or processing HMX may be exposed to the chemical. 

Plant personnel may handle HMX dissolved in various solvents (Army 1984a). The National 

Occupational Exposure Survey (NOES) estimated that six technicians for research and development 

laboratories were potentially exposed to HMX in the United States between 1981-1983 (Sieber et al. 

1991). The NOES database does not contain data on the frequency, duration, concentration, or route 

of exposure of workers to chemicals. 

5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 

Residents or workers near hazardous waste sites containing HMX wastes or manufacturing or 

processing facilities handling explosives are at greater risk of exposure to HMX than the general 

population. 

5.7 ADEQUACY OF THE DATABASE 

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 

the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 

adequate information on the health effects of HMX is available. Where adequate information is not 

available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of 

research designed to determine the health effects (and techniques for developing methods to determine 

such health effects) of HMX. 

The following categories of possible data needs have been identified by a joint team of scientists from 

ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 

reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 

that all data needs discussed in this section must be filled. In the future, the identified data needs will 

be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
HMX 71 

5. POTENTIAL FOR HUMAN EXPOSURE 

5.7.1 Identification of Data Needs 

Physical and Chemical Properties. The physical and chemical properties of HMX are 

sufficiently well characterized to allow estimation of its environmental fate (see Table 3-2) (Army 

1989; EPA 1988; HSDB 1995). On this basis, it does not appear that further research in this area is 

required. 

Production, Import/Export, Use, Release, and Disposal. HMX is manufactured by only one 

facility in the United States (Army 1984a, 1989; EPA 1986). Current production volumes, both as a 

primary product and as a by-product in RDX, and import and export information are not available. 

Current amounts of this chemical consumed by each use were not located. Current information on the 

amounts of HMX released to the environment and disposed by various treatment methods are also not 

available. This information would be helpful in assessing potential exposure to workers and the 

general population. 

According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 

11023, industries are required to submit substance release and off-site transfer information to the EPA. 

The Toxics Release Inventory (TRI), which contains this information for 1992, became available in 

May of 1994. This database will be updated yearly and should provide a list of industrial production 

facilities and emissions. However, HMX is currently not listed in the TRI database. 

Environmental Fate. The environmental fate of HMX has been investigated in several studies 

(Army 1982b, 1983, 1984b, 1984d). The chemical is relatively unreactive and degrades slowly in 

environmental media. It is not likely that exposure to the general population is of concern. 

Nevertheless, because it appears to be persistent in aquatic and terrestrial environments and may 

migrate to groundwater (Army 1982b, 1984b), additional studies might be useful to assess the potential 

for transport of this chemical from hazardous waste sites. In addition, determining the effect of 

chlorination on HMX degradation rates would be useful in predicting potential exposure via drinking 

water. 
HMX 72 

5. POTENTIAL FOR HUMAN EXPOSURE 

Bioavailability from Environmental Media. No studies were located regarding the bioavailability 

of HMX from environmental media. However, studies in rodents indicate that HMX is not well 

absorbed (<5%) in the gastrointestinal tract following exposure by gavage or in the diet (Army 1985g, 

1986). Based on a log Koc value of 0.54 (Army 1989), interactions between HMX and soil may 

decrease bioavailability to some extent, but this is not expected to be significant. Studies which 

investigate the bioavailability of HMX from environmental media would be useful in estimating 

exposure to persons who live near hazardous waste sites contaminated with HMX. 

Food Chain Bioaccumulation. No data on bioconcentration of HMX by aquatic organisms were 

located. Based on data for RDX, food chain bioaccumulation is unlikely, but information on the 

bioconcentration potential of this chemical would be useful to confirm this assumption. 

Exposure Levels in Environmental Media. Reliable monitoring data for the levels of HMX in 

contaminated media at hazardous waste sites are needed so that the information obtained on levels of 

HMX in the environment can be used in combination with the known body burden of HMX to assess 

the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 

sites. Monitoring data were not located for HMX in ambient air or soil. The chemical has been 

detected in surface waters receiving effluents from HMX manufacturing and processing facilities. 

Since this chemical is not expected to be prevalent in the environment and exposure of the general 

population is not expected to be of concern, monitoring of ambient environmental media does not 

appear to be required. However, monitoring of environmental media (particularly tap water from 

surface water sources) in the vicinity of HMX manufacturing and processing facilities, and at 

hazardous waste sites at which HMX has been detected, would help determine potential sources and 

magnitude of exposure. 

Exposure Levels in Humans. No data were located regarding exposure levels of HMX to 

humans. This information is necessary for assessing the need to conduct health studies on these 

populations. Since HMX does not appear to be well absorbed, analyzing blood or urine of workers 

potentially exposed to the chemical is unlikely to provide useful information unless the exposure levels 

are very large. Analysis of feces, although impractical for large scale monitoring, might provide 

documentation of oral exposure. 
HMX 73 

5. POTENTIAL FOR HUMAN EXPOSURE 

Exposure Registries. No exposure registries for HMX were located. This substance is not 

currently one of the compounds for which a subregistry has been established in the National Exposure 

Registry. The substance will be considered in the future when chemical selection is made for 

subregistries to be established. The information that is amassed in the National Exposure Registry 

facilitates the epidemiological research needed to assess adverse health outcomes that may be related 

to exposure to this substance. 

5.7.2 On-going Studies 

Current research on the environmental fate of HMX involves studies of biological waste management 

including the anaerobic degradation of HMX and the effectiveness of white rot fungus in degrading 

HMX for bioremediation of contaminated soil and water (FEDRIP 1995). 

HMX 75 

6. ANALYTICAL METHODS
 

The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 

measuring, and/or monitoring HMX, its metabolites, and other biomarkers of exposure and effect to 

HMX. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to 

identify well-established methods that are used as the standard methods of analysis. Many of the 

analytical methods used for environmental samples are the methods approved by federal agencies and 

organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). 

Other methods presented in this chapter are those that are approved by groups such as the Association 

of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). 

Additionally, analytical methods are included that modify previously used methods to obtain lower 

detection limits, and/or to improve accuracy and precision. 

6.1 BIOLOGICAL MATERIALS 

Reverse-phase high performance liquid chromatography (HPLC) is the preferred method for detecting 

and quantifying HMX in rodent plasma (Army 1985g), and has also been used to analyze rodent urine 

and fecal samples (Army 1986). This method should be applicable to analysis of human biological 

samples, as well. The liquid chromatograph separates mixtures of organics and allows individual 

compounds to be identified and quantified by a detector. An ultraviolet (UV) detector is used for 

quantitation of HMX. Thin layer chromatography (TLC) has also been used for analysis of 14C-HMX 

in urine and fecal samples, but this method is not applicable to unlabeled HMX analysis (Army 1986). 

Prior to analysis, HMX must be separated from the biological sample matrix and prepared for 

introduction into the analytical instrument. Separation from plasma is accomplished by extraction with 

methylene chloride, followed by drying to remove the solvent, and dissolution in a mixture of 

perchloric acid and acetonitrile prior to injection onto the HPLC column (Army 1985g). Extraction 

with acetonitrile separates HMX from urine and fecal samples (Army 1986). Details of methods for 

HMX analysis in biological samples are summarized in Table 6- 1. 

HMX 77 

6. ANALYTICAL METHODS 

6.2 ENVIRONMENTAL SAMPLES 

Several methods have been developed to detect HMX in water and soil. Representative methods for 

quantifying HMX in these media are summarized in Table 6-2. Only one analytical method for HMX 

in air was located (OSHA 1987). This method has been only partially evaluated and is presented for 

information and trial use. The method is summarized in Table 6.2. 

The primary method for determining HMX in water and soil samples is by HPLC analysis (Army 

1984c, 1985i, 1991c; Bauer et al. 1986, 1990; Jenkins et al. 1986, 1989; Maskarinec et al. 1984; 

Phillips et al. 1994). The U.S. EPA has issued a reverse-phase high-performance liquid 

chromatographic (RP-HPLC) method (Method 8330) for the determination of nitroaromatic and 

nitramine explosives in environmental samples (EPA 1992). The American Society for Testing and 

Materials (see ASTM 1991) and the Association of Official Analytical Chemists (AOAC 1990) have 

also adopted an HPLC method as the standard method for determining explosive residues in soil and 

water (AOAC 1990; Army 1984c; Bauer et al. 1986, 1990; Jenkins et al. 1986, 1989). Gas 

chromatography (GC) and thin-layer chromatography (TLC) may also be employed (Glover and 

Hoffsommer 1973; Hable et al. 1991). 

Separation of HMX from environmental samples is usually accomplished by extraction with an organic 

solvent such as methanol, isoamyl acetate, or acetonitrile (Army 1984c, 1985i; Bauer et al. 1986, 

1990; Bongiovanni et al. 1984; Jenkins et al. 1989; Phillips et al. 1994). Method 8330 recommends a 

salting-out procedure with sodium chloride and acetonitrile for low concentrations of explosive 

residues in surface or groundwater, direct injection for water samples of higher concentrations, and 

extraction by acetonitrile in an ultrasonic bath for soil and sediment samples (EPA 1992). Research to 

improve these extraction methods is still in progress. A recent study was conducted to evaluate the 

use of supercritical fluids for the extraction of explosive residues from soils in an attempt to improve 

the efficiency, specificity, and time and solvent requirements of extraction (Thorne 1994). This study, 

however, concluded that supercritical fluid extraction was not a practical method for the routine 

extraction of explosive residues from soils. 

Identification and quantification is most frequently done by UV (Army 1984c, 1985i; Bauer et al. 

1986, 1990; Bongiovanni et al. 1984; Glover and Hoffsommer 1973; Jenkins et al. 1989), but an 



HMX 81 

6. ANALYTICAL METHODS 

electron capture detector (ECD), thermal energy analyzer (TEA), or electrochemical detector (ED) may 

also be used (Fine et al. 1984; Hable et al. 1991; Maskarinec et al. 1984). When unequivocal 

confirmation is required, mass spectrometry (MS) may be employed (Hable et al. 1991). 

Accurate determination of HMX in environmental samples is complicated by its low vapor pressure 

and susceptibility to thermal degradation (EPA 1988), thus compromising the usefulness of GC 

methods for separation of this compound from complex mixtures. This problem has recently been 

overcome by limiting contact of the compound with metal parts in the injection port, deactivating the 

injection port liner by acid treatment, and employing direct flash rather than splitless injection (Hable 

et al. 1991). 

Due to lack of experimental data for HMX, EPA specified a maximum holding time (MHT) for 

preextraction samples of seven days (the same as for semivolatile organics) (EPA 1992). 

Subsequently, the stability of HMX in laboratory samples was evaluated (Army 1991b; Grant et al. 

1993a, 1993b). The MHT for HMX was experimentally evaluated in reagent-grade water, 

groundwater, and surface water (Grant et al. 1993a). Samples were held for a period of up to 70 days 

at both room temperature (22°C) and under refrigeration (2°C). HMX was stable over the entire 

period for all waters under both storage temperatures (Grant et al. 1993a). Studies to evaluate the 

MHT in soils demonstrated that HMX was stable over the 56-day study period under all conditions 

(Grant et al. 1993b). Further studies on MHT for both water samples and soil samples were conducted 

by Makarinec, Bayne, and Johnson (Army 1991). Based on these studies, the recommended MHT for 

surface water, groundwater, and soil samples prior to analysis for HMX were 30 days, 50 days, and 

56 days respectively (Army 1991b; Grant et al. 1993a, 1993b). All samples should be refrigerated 

during storage. 

6.3 ADEQUACY OF THE DATABASE 

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 

the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 

adequate information on the health effects of HMX is available. Where adequate information is not 

available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of 

research designed to determine the health effects (and techniques for developing methods to determine 

such health effects) of HMX. 
HMX 82 

6. ANALYTICAL METHODS 

The following categories of possible data needs have been identified by a joint team of scientists from 

ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 

reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 

that all data needs discussed in this section must be filled. In the future, the identified data needs will 

be evaluated and prioritized, and a substance-specific research agenda will be proposed. 

6.3.1 Identification of Data Needs 

Methods for Determining Biomarkers of Exposure and Effect 

Exposure. Methods exist for determining the levels of HMX in plasma, tissues, urine, and feces in 

animals (Army 1985g, 1986), which are presumably applicable to human exposures, as well. These 

methods are reasonably accurate, reliable, and specific for determining exposures to HMX. Since 

HMX is poorly absorbed in the gastrointestinal tract, the levels in plasma, tissues, and urine are likely 

to be lower than those detected in the feces following oral exposure. The data are too limited to 

determine if these methods are sufficiently sensitive for measuring the levels at which biological 

effects are expected to occur. Most people are not exposed to HMX; therefore the background levels 

of HMX in the general population are not expected to be detectable. Since HMX is metabolized to 

polar intermediates in the body, studies which identify these intermediates, in conjunction with studies 

which develop sensitive and reliable methods for detecting and quantifying these intermediates, would 

be useful for medical surveillance in the future. 

Effect. Methods exist for measuring serum enzyme activities and brain wave alterations which could 

be used as biomarkers of the hepatic and neurological effects of HMX. These methods are sufficiently 

sensitive for measuring background levels in unexposed populations and could be used to determine 

the levels at which biological effects occur. However, these types of effects are common to exposures 

to a large number of exogenous compounds and endogenous diseases and illnesses and, therefore, are 

not specific biomarkers of effect for HMX exposure. Studies which identify specific biomarkers of 

effect for HMX, in conjunction with studies that develop sensitive and reliable methods for detecting 

these biomarkers, would be useful in determining if significant exposure to HMX has occurred. 
HMX 83 

6. ANALYTICAL METHODS 

Methods for Determining Parent Compounds and Degradation Products in 

Environmental Media. Analytical methods are available to detect and quantify HMX in water and 

soil (Army 1984c, 1985i, 1991c; Bauer et al. 1986, 1990; Bongiovanni et al. 1984; EPA 1992; Glover 

and Hoffsommer 1973; Hable et al. 1991; Jenkins et al. 1986, 1989, 1992; Major 1992; Maskarinec 

et al. 1984). Water is the medium of most concern for human exposure to this chemical. Exposure 

may also occur from soil or sediments in the vicinity of hazardous waste sites or from manufacturing 

or processing sources. The existing analytical methods can provide determinations for HMX at levels 

sufficiently low to meet water quality guidelines and below which health effects may occur (Army 

1991c; Hable et al. 1991). However, improved methods of extraction and analysis that minimize 

interferences and decomposition would enhance recovery of lower levels of HMX that may be present 

in soil and in drinking water at hazardous waste sites and at military manufacturing and processing 

facilities. Research to improve the available methods is in progress (see Section 6.3.2). No 

information was located on specific analytical methodology for HMX in air samples. Development of 

a simple method for sampling and analyzing workplace air would be helpful in assessing the potential 

for human exposure from this source. 

Methods are also available to measure degradation products of HMX in environmental samples (Army 

1983), but these products (mainly nitrate, nitrite, and formaldehyde) are released to the environment 

from many other sources and are therefore not useful determinants of the environmental impact of this 

chemical. 

6.3.2 On-going Studies 

On-going research to improve analytical methods for HMX and related compounds includes studies to 

facilitate efficient elution of HMX using mobile phase modifiers and/or more inert capillary columns, 

thus enabling detection and quantitation of HMX by these methods. Research continues on developing 

improved techniques for extraction, concentration, and elution of HMX (Army 1991c; Bauer et al. 

1990; Berberich et al. 1988; Hable et al. 1991). These improvements are designed to oVercome 

problems with sample preparation and increase sensitivity and reliability of the analyses. 

HMX 85 

7. REGULATIONS AND ADVISORIES 

Because of its potential to cause adverse health effects in exposed people, numerous regulations and 

advisories have been established for HMX by various national agencies. Major regulations and 

advisories pertaining to HMX are summarized in Table 7- 1. 

ATSDR has derived an acute oral MRL of 0.1 mg/kg/day for HMX. The MRL is based on a LOAEL 

of 100 mg/kg/day for neurological effects in mice exposed for 14 days (Army 1985d). The LOAEL 

value was divided by an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for extrapolation 

from animal to humans, and 10 for human variability). 

ATSDR has derived an intermediate oral MRL of 0.05 mg/kg/day for HMX. The MRL is based on a 

NOAEL of 50 mg/kg/day for hepatic effects in rats exposed for 13 weeks (Army 1985c). The 

NOAEL value was divided by an uncertainty factor of 100 (10 for extrapolation from animal to 

humans 10 for human variability) and a modifying factor of 10 for use of a “limited database” and 

data indicating that mice may be more sensitive than rats. 

EPA has derived a chronic oral RfD of 0.05 mg/kg/day for HMX (IRIS 1995; EPA 1995). This value 

is based on a NOAEL of 50 mg/kg/day for liver lesions in rats exposed for 13 weeks (Army 1985c). 

The NOAEL was divided by an uncertainty factor of 1,000 to account for extrapolation from animals 

to humans, uncertainty in the threshold for sensitive humans, and extrapolation from subchronic 

exposure to chronic exposure. 

___________ 

HMX 87 

8. REFERENCES
 

Anonymous. 1986. TNT, RDX, HMX, and 2,4-DNT in waste water and groundwater liquid 

chromatographic method first action. In: Changes in methods. J Assoc Off Anal Chem 69:366-367. 

*AOAC. 1990. TNT, RDX, HMX, and 2,4-DNT in waste water and groundwater. Liquid 

chromatographic method - 986.22. AOAC Official Methods of Analysis. 15th Ed. Arlington, VA: 

Association of Official Analytical Chemists. 

*Army. 1974. The toxicology of cyclotrimethylenetrinitramine (RDX) and 

cyclotetramethylenetetranitramine (HMX) solutions in dimethylsulfoxide (DMSO), cyclohexanone, and 

acetone. Aberdeen Proving Ground, MD: Edgewood Arsenal. AD-780 010. (authored by McNamara 

et al.) 

*Army. 1977a. Final report on toxicological investigations of pilot treatment plant waste waters at 

Holston Army Ammunition Plant. Washington, DC: U.S. Army Medical Research and Development 

Command. Columbus, OH: Battelle Columbus Laboratories. (authored by Stilwell et al.) 

Army. 1977b. Munitions environmental quality standards research status report. Washington, DC: 

U.S. Army Medical Research and Development Command. AD-A956 091. (authored by Glennon et 

al.) 

*Army. 1977c. Mutagenicity of some munitions waste water chemicals and chlorine test kit reagents. 

Final Report. Menlo Park, CA: SRI International. (authored by Simmon et al.) 

Army. 1979. Mammalian toxicity of munitions compounds identification of waste products from RDX 

and HMX manufacture. Kansas City, MO: Midwest Research Institute, U.S. Army Medical 

Bioengineering Research and Development Laboratory AD-A074505. (authored by Helton et al.) 

Army. 1982a. Environmental fate studies of HMX screening studies. Final Report, Phase I. Menlo 

Park, CA: SRI International. AD-Al48 978. (authored by Spanggord et al.) 

*Army. 1982b. Migration of explosives in soil. Silver Springs, MD: Naval Surface Weapons Center, 

NSWC TR 82-566. (authored by Kayser EG, Burlinson NE). 

*Army. 1983. Environmental fate studies of HMX Phase II-detailed studies. Final Report. Menlo 

Park, CA: SRI International. AD-A145 122. (authored by Spanggord et al.) 

*Army. 1984a. Database assessment of the health and environmental effects of munitions production 

waste products. Oak Ridge, TN: Oak Ridge National Laboratory, Chemical Effects Information Center, 

ORNL-6018. AD-A145 417 (authored by Ryon et al.) 

*Cited in text 
HMX 88 

8. REFERENCES 

*Army. 1984b. Degradation of pink water compounds in soil - TNT, RDX, HMX. Natick, MA: 

United States Army Natick Research and Development Center, Science and Advanced Technology 

Laboratory. Technical Report NATICWTR-85/046. (authored by Greene et al.) 

*Army. 1984~. Reverse phase HPLC method of analysis of TNT, RDX, HMX and 2,4-DNT in 

munitions waste water. Hanover, NH: U.S. Army Cold Regions Research and Engineering Laboratory, 

CRREL Report 84-29. AD-A155-983 (authored by Jenkins et al.) 

*Army. 1984d. The anaerobic biotransformation of RDX, HMX, and their acetylated derivatives. 

Natick, MA: U.S. Army Natick Research and Development Center, NaticWTR-85/007. (authored by 

McCormick et al.) 

*Army. 1985a. Determination of the acute and subchronic mammalian toxicity of HMX. Frederick, 

MD: U.S. Army Medical Research and Development Command. AD-Al73 743. (authored by Wilson 

AB) 

*Army. 1985b. HMX: 13 week toxicity study in mice by dietary administration. Ft. Detrick, MD: 

U.S. Army Medical Research and Development Command, U.S. Army Medical Bioengineering Research 

and Development Laboratory. (authored by Everett DJ and Maddock SM) 

*Army. 1985c. HMX: 13 week toxicity study in rats by dietary administration. Ft. Detrick, MD: 

U.S. Army Medical Research and Development Command, U.S. Army Medical Bioengineering Research 

and Development Laboratory. (authored by Everett et al.) 

*Army. 1985d. HMX: 14-day toxicity study in mice by dietary administration. Ft. Detrick, MD: 

Research and Development Command, U.S. Army Medical Bioengineering Research and Development 

Laboratory. (authored by Greenough RJ, McDonald P). 

*Army. 1985e. HMX: 14-day toxicity study in rats by dietary administration. Ft. Detrick, MD: 

Research and Development Command, U.S. Army Medical Bioengineering Research and Development 

Laboratory. AD-A171 597 (authored by Greenough RJ, McDonald P). 

Army. 1985f. HMX: analysis of dosing formulation used in acute, sub-acute and sub-chronic toxicity 

studies. Frederick, MD: U.S. Army Medical Research and Development Command. AD-A171 595. 

(authored by Henderson MS) 

*Army. 1985g. HMX: analysis in plasma obtained after 90 day toxicity studies with rats and mice. 

Frederick, MD: U.S. Army Medical Research and Development Command. AD-Al71 603. (authored 

by Henderson MS) 

*Army. 1985h. HMX: Acute toxicity tests in laboratory animals. Ft. Detrick, MD: US. Army 

Medical Research and Development Command. Report No. 2051. (authored by Cuthbert et al.) 

*Army. 1985i. TNT, RDX, and HMX explosives in soils and sediments. Hanover, NH: US. Army 

Cold Regions Research and Engineering Laboratory. CRREL Report 85-15. (authored by Cragin et al.) 

*Army. 1986. HMX: toxicokinetics of 14C-HMX following oral administration to the rat and mouse 

and intravenous administration to the rat. Frederick, MD: U.S. Army Medical Bioengineering Research 

and Development Laboratory. IRI Report No. 2588. AD-A171 600. (authored by Cameron BD) 
HMX 89 

8. REFERENCES 

*Army. 1989. Organic explosives and related compounds: environmental and health considerations. 

Frederick, MD: U.S. Army Medical Research & Development Command. Technical Report 8901. 

(authored by Burrows et al.) 

Army. 1990. Environmental transformation products of nitroaromatics and nitramines. Literature 

review and recommendations for analytical method development. Hanover, NH: U.S. Army Cold 

Regions Research and Engineering Laboratory. CETHA-TE-CR-89205. (authored by Walsh ME) 

Army. 1991a. Optimization of cornposting for explosives contaminated soil. West Chester, PA: Roy 

F. Weston, Inc. U.S. Army Toxic and Hazardous Materials Agency, CETHA-TS-CR-91053. (authored 

by Williams and Marks) 

*Army. 1991b. Stability of explosives in environmental water and soil samples. Oak Ridge, TN: Oak 

Ridge National Laboratory, ORNL/TM--11770. (authored by Maskarinec et al.) 

*Army. 1991c. Improved salting out extraction-preconcentration method for the determination of 

nitroaromatics and nitramines in water. Hanover, NH: U.S. Army Cold Regions Research and 

Engineering Laboratory, CRRELA Special Report 91-18, AD-A245-491 (authored by Miyares PH, 

Jenkins TF). 

*ASTM. 1991. Methods for analysis of nitroaromatics and nitroamine explosives in soil by high 

performance liquid chromatography. American Society for Testing and Materials. Method D5143-90. 

ATF. 1993. Bureau of Alcohol, Tobacco and Firearms. Federal Register 58:4736-4738. 

*ATSDR. 1989. Agency for Toxic Substances and Disease Registry. Part V. Federal Register 

54:37619-37633. 

*ATSDR. 1993. Agency for Toxic Substances and Disease Registry. Toxicological profile for 

hydrazines (Draft). Atlanta, GA: Agency for Toxic Substances and Disease Registry. 

*Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk 

assessments. Regul Toxicol Pharmacol 8:471-486. 

*Bauer CF, Grant CL, Jenkins TF. 1986. Interlaboratory evaluation of high-performance liquid 

chromatographic determination of nitroorganics in munitions plant waste water. Anal Chem 58:176-182. 

*Bauer CF, Koza SM, Jenkins TF. 1990. Liquid chromatographic method for determination of 

explosives residues in soil: collaborative study. J Assoc Off Anal Chem 73:541-552. 

*Berberich DW, Yost RA, Fetterolf DD. 1988. Analysis of explosives by liquid 

chromatography/thermospray/mass spectrometry. J Forensic Sci 946-959. 

*Bongiovanni R, Podolak GE, Clark LD, et al. 1984. Analysis of trace amounts of six selected polynitro 

compounds in soils. Am Ind Hyg Assoc J 45:222-226. 

*Checkai R, Major M, Nwanguma R, et al. 1993. Transport and fate of nitroaromatic and nitramine 

explosives in soils from open burning/open detonation operations: Milan Army Ammunition Plant. 

Aberdeen, MD: Edgewood Research, Development, and Engineering Center. AD-A279 145. 
HMX 90 

8. REFERENCES 

*Department of State. 1992. Federal Register 57:15227-15237. 

DOT. 1990. Department of Transportation. Part II. Federal Register 55:18438-18442, 18449, 18479. 

*Ellenhorn MJ, Barceloux DG. 1988. Medical toxicology: Diagnosis and treatment of human 

poisoning. New York, NY: Elsevier, 82, 850. 

*EPA. 1986. U.S. Environmental Protection Agency. Federal Register 51:35372-35376. 

*EPA. 1988. Health advisory for octahydro-1,3,5,7-tetranitro 1,3,5,7-tetrazocine (HMX). Washington, 

DC: U.S. Environmental Protection Agency, Office of Drinking Water. (authored by McLellan et al.) 

*EPA. 1990. U.S. Environmental Protection Agency. Part II. Federal Register 55:22520-22537, 

22593, 22712. 

*EPA. 1992. SW 846 Method 8330: Nitroaromatics and nitramines by high performance liquid 

chromatography (HPLC). Washington, DC: Environmental Protection Agency 8330:1-21 

*EPA. 1994. EPA Superfund Record of Decision (EPA Region 4): Milan Army Ammunition Plant, 

Operable Unit 3, Milan, TN. Office of Emergency Medical Response. EPA/ROD/R04-94/199. 

*EPA. 1995. Drinking water regulations and health advisories. Washington, DC: US Environmental 

Protection Agency, Office of Water. 

Farber M. 1992. Mass-spectrometric investigations of the thermal-decomposition of 1,3,5,7-tetranitro1,3,5,7-tetraazacyclooctane (HMX) and 1,3,5-trinitro-1,3,5-triazacyclohexane (RDX). Mass 

Spectrometry Reviews 11:137-152. 

*FEDRIP. 1995. Federal Research In Progress. Dialog. Information Services, Inc. March 1995. 

Fernando T, Aust S. 1991. Biological decontamination of water contaminated with explosives by 

Phanerochaete chrysosporium. Gas, Oil, Coal, Environmental Biotechnology 3:193-206. 

*Fine DH, Yu WC, Goff EU, et al. 1984. Picogram analyses of explosive residues using the thermal 

energy analyzer (TEA). J Forensic Sci 732-746. 

FSTRAC. 1990. Summary of state and federal drinking water standards and guidelines. Washington, 

DC: Federal-State Toxicology and Regulatory Alliance Committee, Chemical Communication 

Subcommittee. Report 7, p. 17. 

*Glover DJ, Hoffsommer JC. 1973. Thin-layer chromatographic analysis of HMX in water. Bull 

Environ Contam Toxicol 10:302-304. 

*Grant CL, Jenkins TF, Golden SM. 1993a. Evaluation of pre-extraction holding times for 

nitroaromatic and nitramine explosives in water. Hanover, NH: USA Cold Regions Research and 

Engineering Laboratory. CRREL Special Report 93-24, AD-A271 547. 
HMX 91 

8. REFERENCES 

*Grant CL, Jenkins TF, Golden SM. 1993b. Experimantal assessment of analytical holding times for 

nitroaromatic and nitramine explosives in soil. Hanover, NH: USA Cold Regions Research and 

Engineering Laboratory. CRREL Special Report 93-11, AD-A269 721. 

*Hable M, Stem C, Asowata C, et al. 1991. The determination of nitroaromatics and nitramines in 

ground and drinking water by wide-bore capillary gas chromatography. J Chromatogr Sci 29: 131-135. 

*Hathaway JA, Buck CR. 1977. Absence of health hazards associated with RDX manufacture and use. 

J Occup Med 19:269-272. 

*HazDat. 1995. Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, GA. 

*HSDB. 1995. Hazardous substances data bank. National Library of Medicine, National Toxicology 

Information Program, Bethesda, MD. March 8, 1995 

*IRIS. 1995. Integrated Risk Information System. U.S. Environmental Protection Agency, 

Washington, DC. March 8, 1995. 

*Jenkins T, Miyares P, Myers K, et al. 1992. Comparison of cartridge and membrane solid-phase 

extraction with salting-out solvent extraction for preconcentration of nitroaromatic and r&amine 

explosives from water. Hanover, NH: USA Cold Regions Research and Engineering Laboratory. ADA260 

177. 

*Jenkins TF, Leggett DC, Grant CL, et al. 1986. Reversed-phase high-performance liquid 

chromatographic determination of nitroorganics in munitions waste water. Anal Chem 58:170-175. 

*Jenkins TF, Walsh ME, Schumacher PW, et al. 1989. Liquid chromatographic method for 

determination of extractable nitroaromatic and nitramine residues in soil. J Assoc Off Anal Chem 

72:890-899. 

Kotiaho T, Lauritsen FR, Choudhoury TK, et al. 1991. Membrane introduction mass spectrometry. 

Anal Chem 63:875-833. 

Lloyd JB. 1983. High-performance liquid chromatography of organic explosives components with 

electrochemical detection at a pendant mercury drop electrode. J Chromatogr 257:227-236. 

*Major MA, Checkai RT, Phillips CT, et al. 1992. Method for screening and analysis of residues 

common to munition open burning/open detonation (OB/OD) sites. Int J Environ Anal Chem 48:217­

227. 

*Maskarinec MP, Manning DL, Harvey RW, et al. 1984. Determination of munitions components in 

water by resin adsorption and high-performance liquid chromatography-electrochemical detection. J 

Chromatogr 302:5 l-63. 

*NAS/NRC. 1989. Biologic markers in reproductive toxicology. Washington, DC: National Academy 

of Sciences, National Research Council, National Academy Press. 
HMX 92 

8. REFERENCES 

*OSHA. 1987. HMX Analytical Method. Salt Lake City, UT: Pesticides and Carcinogen Branch, 

OSHA Analytical Laboratory. 

*Phillips C, Checkai R, Chester N, et al. 1994. Toxicity testing of soil samples from Joliet Army 

Ammunition Plant, IL. Aberdeen, MD: Edgewood Research, Development, and Engineering Center. 

AD-A279 091. 

*Phillips C, Checkai R, Wentsel R. 1993. Toxicity of selected munitions and munition-contaminated 

soil on the earthworm (Eiseniafoetidu). Aberdeen, MD: Edgewood Research, Development, and 

Engineering Center. AD-A264 408. 

Sax NI, Lewis RJ Sr. 1989. Dangerous properties of industrial materials. 7th ed. Vol. II. New York, 

NY: Van Nostrand Reinhold Company 1015. 

*Sieber W, Sundin D, Frazier T, et al. 1991. Development, use and availability of a job exposure 

matrix based on national occupational hazard survey data. Am J Ind Med 20:163:174. 

*Tan EL, Ho CH, Griest WH. 1992. Mutagenicity of trinitrotoluene and its metabolites formed during 

cornposting. J Toxicol Environ Health 36: 165 175. 

*Thorne P. 1994. Evaluation of the use of supercritical fluids for the extraction of explosives and their 

degradation products from soil. Hanover, NH: USA Cold Regions Research and Engineering 

Laboratory. CRREL Special Report 94-9. AD-A282 338. 

*Whong WZ, Speciner ND, Edwards GS. 1980. Mutagenic activity of tetryl, a nitroaromatic explosive, 

in three microbial test systems. Toxicol Lett 5:11-17. 

Williams RT, Ziegenfuss PS, Sisk WE. 1992. Composting of explosives and propellant contaminated 

soils under thermophilic and mesophilic conditions. J Ind Microbial 9:137-144. 

HMX 93 

9. GLOSSARY 

Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, as specified in the 

Toxicological Profiles. 

Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical adsorbed per unit weight of 

organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 

Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 

phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid 

phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per 

gram of soil or sediment. 

Bioconcentration Factor (BCF) -- The quotient of the concentration of a chemical in aquatic organisms 

at a specific time or during a discrete time period of exposure divided by the concentration in the 

surrounding water at the same time or during the same period. 

Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group of studies, that 

produces significant increases in the incidence of cancer (or tumors) between the exposed population 

and its appropriate control. 

Carcinogen -- A chemical capable of inducing cancer. 

Ceiling Value -- A concentration of a substance that should not be exceeded, even instantaneously. 

Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified in the Toxicological 

Profiles. 

Developmental Toxicity -- The occurrence of adverse effects on the developing organism that may 

result from exposure to a chemical prior to conception (either parent), during prenatal development, or 

postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any 

point in the life span of the organism. 

Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a result of prenatal exposure 

to a chemical; the distinguishing feature between the two terms is the stage of development during 

which the insult occurred. The terms, as used here, include malformations and variations, altered 

growth, and in utero death. 

EPA Health Advisory -- An estimate of acceptable drinking water levels for a chemical-substance 

based on health effects information. A health advisory is not a legally enforceable federal standard, but 

serves as technical guidance to assist federal, state, and local officials. 

Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental concentration of a 

contaminant from which one could escape within 30 min without any escape-impairing symptoms or 

irreversible health effects. 
HMX 94 

9. GLOSSARY 

Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days, as specified in the 

Toxicological Profiles. 

Immunologic Toxicity -- The occurrence of adverse effects on the immune system that may result from 

exposure to environmental agents such as chemicals. 

In Vitro -- Isolated from the living organism and artificially maintained, as in a test tube. 

In Vivo -- Occurring within the living organism. 

Lethal Concentration(Lo) (LCLo) -- The lowest concentration of a chemical in air which has been 

reported to have caused death in humans or animals. 

Lethal Concentration(50) (LC50) -- A calculated concentration of a chemical in air to which exposure for 

a specific length of time is expected to cause death in 50% of a defined experimental animal population. 

Lethal Dose(Lo) ( LDLo) -- The lowest dose of a chemical introduced by a route other than inhalation 

that is expected to have caused death in humans or animals. 

Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated to cause death in 50% of a 

defined experimental animal population. 

Lethal Time(50)(LT50) -- A calculated period of time within which a specific concentration of a 

chemical is expected to cause death in 50% of a defined experimental animal population. 

Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in a study, or group 

of studies, that produces statistically or biologically significant increases in frequency or severity of 

adverse effects between the exposed population and its appropriate control. 

Malformations -- Permanent structural changes that may adversely affect survival, development, or 

function. 

Minimal Risk Level -- An estimate of daily human exposure to a dose of a chemical that is likely to be 

without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 

Mutagen -- A substance that causes mutations. A mutation is a change in the genetic material in a 

body cell. Mutations can lead to birth defects, miscarriages, or cancer. 

Neurotoxicity -- The occurrence of adverse effects on the nervous system following exposure to 

chemical. 

No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which there were no 

statistically or biologically significant increases in frequency or severity of adverse effects seen between 

the exposed population and its appropriate control. Effects may be produced at this dose, but they are 

not considered to be adverse. 

Octanol-Water Partition Coefficient (Kow) -- The equilibrium ratio ‘of the concentrations of a chemical 

in n-octanol and water, in dilute solution. 
HMX 95 

9. GLOSSARY 

Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace air averaged over an 

8-hour shift. 

q1 * -- The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 

multistage procedure. The q,* can be used to calculate an estimate of carcinogenic potency, the 

incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 

μg/m3

 for air). 

Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an order of magnitude) of the 

daily exposure of the human population to a potential hazard that is likely to be without risk of 

deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal 

and human studies) by a consistent application of uncertainty factors that reflect various types of data 

used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of 

the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer. 

Reportable Quantity (RQ) -- The quantity of a hazardous substance that is considered reportable under 

CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 

established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities 

are measured over a 24-hour period. 

Reproductive Toxicity -- The occurrence of adverse effects on the reproductive system that may result 

from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 

endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 

fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 

this system. 

Short-Term Exposure Limit (STEL) -- The maximum concentration to which workers can be exposed 

for up to 15 min continually. No more than four excursions are allowed per day, and there must be at 

least 60 min between exposure periods. The daily TLV-TWA may not be exceeded. 

Target Organ Toxicity -- This term covers a broad range of adverse effects on target organs or 

physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 

exposure to those assumed over a lifetime of exposure to a chemical. 

Teratogen -- A chemical that causes structural defects that affect the development of an organism. 

Threshold Limit Value (TLV) -- A concentration of a substance to which most workers can be 

exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 

Time-Weighted Average (TWA) -- An allowable exposure concentration averaged over a normal 

8-hour workday or 40-hour workweek. -. 

Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route other than inhalation, 

which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
HMX 96 

9. GLOSSARY 

Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD from experimental data. 

UFs are intended to account for (1) the variation in sensitivity among the members of the human 

population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in 

extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty 

in using LOAEL data rather than NOAEL data. Usually each of these factors is set equal to 10. 
 

HMX A-1 

APPENDIX A 

MINIMAL RISK LEVEL WORKSHEETS 

Chemical Name: HMX 

CAS Number: 2691-41-0 

Date: June 6, 1997 

Profile Status: Final (Post-Public Comment) 

Route: [ ] Inhalation [xl Oral 

Duration: [xl Acute [ ] Intermediate [ ] Chronic 

Graph Key: 13 

Species: Mouse 

Minimal Risk Level: 

0.1 [X] mg/kg/day [ ] ppm 

Reference: 

Army. 1985d. HMX: 14-day toxicity study in mice by dietary administration. Ft. Detrick, MD: 

Research and Development Command, U.S. Army Medical Bioengineering Research and Development 

Laboratory. AD-A171 597 (authored by Greenough RJ, McDonald P). 

Experimental design: 

Groups of 6 male and 6 female B6C3Fl mice were administered HMX in the feed for 14 days at the 

following doses: 0 , 100, 300, 900, and 2700 mg/kg/day for males; and 0 , 320, 800, 2000, and 5000 

mg/kg/day for females. 

Effects noted in studv and corresponding doses: 

HMX-treated animals exhibited hyperkinesia when aroused at doses of 100 mg/kg/day. Convulsions 

were observed in two males exposed to 300 mg/kg/day. Other effects including piloerection, hunched 

posture, and increased sensitivity to auditory stimuli were also noted in animals exposed to this dose. 

No mention was made by the authors whether or not convulsions were observed in animals given 

higher doses. Necropsy of the brain did not reveal any abnormalities. 

Dose and end point used for MRL derivation: 100 mg/kg/day hyperkinesia 

[ ] NOAEL [x ] LOAEL 

Uncertaintv factors used in MRL derivation: 

[XI 10 for use of a LOAEL 

[X] 10 for extrapolation from animals to humans 

[X] 10 for human variability 

Was a conversion used from npm in food or water to a mg/bodv weight dose? If so explain: 

NA 
HMX A-2 

APPENDIX A 

If an inhalation studv in animals. list the conversion factors used in determining human equivalent dose:
 

NA
 

MRL Calculation:
 

LOAEL: 100 mg/kg/day
 

MRL = LOAEL/UF = 100/1000 = 0.1 mg/kg/day
 
 

 

HMX A-3 

APPENDIX A 

Chemical Name: HMX 

CAS Number: 2691-41-0 

Date: June 6, 1997 

Profile Status: Final (Post-Public Comment) 

Route: [ ] Inhalation [X] Oral 

Duration: [ ] Acute [X] Intermediate [ ] Chronic 

Graph Key: 16 

Species: Rat 

Minimal Risk Level: 

0.05 [X] mg/kg/day [ ] ppm 

Reference: 

Army. 1985c. HMX: 13 week toxicity study in rats by dietary administration. Ft. Detrick, MD: 

US. Army Medical Research and Development Command, U.S. Army Medical Bioengineering 

Research and Development Laboratory. (authored by Everett et al.) 

Experimental design: 

Groups of 20 male and 20 female Fischer rats were administered HMX in the feed for 13 weeks at the 

following doses: 0 , 50, 150, 450, 1,350, and 4,000 mg/kg/day for males; 0 , 50, 115, 270, 620, and 

1,500 mg/kg/day for females. 

Effects noted in studv and corresponding doses: 

A NOAEL was established for hepatic effects at 50 mg/kg/day. Hepatic effects including enlarged 

centrilobular cells with pale nuclei and dark cytoplasm were observed in males exposed to 150 

mglkgiday or more. In females administered 270 mg/kg/day or more, focal atrophy of the kidney 

tubules and dilatation was observed. Only high-dose animals (1,500 mg/kg/day for females, 4,000 

mg/kg/day for males) were evaluated for serum chemistry parameters. Decreases in hemoglobin, 

packed cell volume, and blood urea nitrogen, and an increase in methemoglobin were observed in 

both males and females, although the elevation in methemoglobin levels was significant in males only. 

In addition, urinary pH was decreased while urinary volume was increased in females administered the 

highest dose. Crystals were observed in the urine of males administered the highest dose. Significant 

body weights were decreased in a dose-dependent manner, and many organ weights (adrenal, brain, 

heart, kidney, spleen, liver, lungs, and ovaries) were affected in a dose-dependent manner, however, 

the dose at which these changes became significant could not be determined. Histological effects were 

seen only in the liver and the kidneys. The results of this study indicate the liver and the kidneys as 

target organs. Ophthalmoscopic examination did not reveal any significant effects on the eyes that 

could be attributed to HMX treatment. Food intake did not show a consistent dose-related trend, but 

was reduced in treated animals as compared to controls. 

Dose and end point used for MRL derivation: 50 mg/kg/day- Hepatic 

[Xl NOAEL [ ] LOAEL 
HMX A-4 

APPENDIX A 

Uncertainy factors used in MRL derivation: 

[X] 10 for extrapolation from animals to humans 

[X] 10 for human variability 

Modifving factors used in MRL derivation: 

[X] 10 for use of a “limited database” and of data indicating that mice may be more sensitive 

than rats 

Supporting studies:
 

Hepatocyte hyperplasia and cytoplasmic eosinophilia were noted in rats and mice exposed to 1,280 and
 

300 mg/kg/day HMX, respectively, for 14 days (Army 1985d, 1985e). No hepatic effects were
 

observed in mice exposed to 90 mg/kg/day HMX (Army 1985b).
 

Was a conversion used from ppm in food or water to a mg/bodv weight dose? If so explain: 

NA 

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 

NA 

MRL Calculation: 

NOAEL: 50 mg/kg/day 

MRL = (NOAEL/UF)/ MF = (50/100)/10 = 0.05 mg/kg/day 

HMX	 B-1 

APPENDIX B 

USER’S GUIDE 

Chapter 1 

Public Health Statement 

This chapter of the profile is a health effects summary written in non-technical language. Its intended 

audience is the general public especially people living in the vicinity of a hazardous waste site or 

chemical release. If the Public Health Statement were removed from the rest of the document, it would 

still communicate to the lay public essential information about the chemical. 

The major headings in the Public Health Statement are useful to find specific topics of concern. The 

topics are written in a question and answer format. The answer to each question includes a sentence 

that will direct the reader to chapters in the profile that will provide more information on the given 

topic. 

Chapter 2 

Tables and Figures for Levels of Significant Exposure (LSE) 

Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects and illustrate 

graphically levels of exposure associated with those effects. These levels cover health effects observed 

at increasing dose concentrations and durations, differences in response by species, minimal risk levels 

(MRLs) to humans for noncancer end points, and EPA’s estimated range associated with an upperbound 

individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures 

for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE 

tables and figures should always be used in conjunction with the text. All entries in these tables and 

figures represent studies that provide reliable, quantitative estimates of No-Observed-Adverse- Effect 

Levels (NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 

The legends presented below demonstrate the application of these tables and figures. Representative 

examples of LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends 

correspond to the numbers in the example table and figure. 

LEGEND 

See LSE Table 2-1 

(1)	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance 

using these tables and figures should be the relevant and appropriate route of exposure. When 

sufficient data exists, three LSE tables and two LSE figures are presented in the document. The 

three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and 

dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE 

Figure 2-l) and oral (LSE Figure 2-2) routes. Not all substances will have data on each route of 

exposure and will not therefore have all five of the tables and figures. 

(2)	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15-364 days), 

and chronic (365 days or more) are presented within each relevant route of exposure. In this 

example, an inhalation study of intermediate exposure duration is reported. For quick reference to 
HMX	 B-2 

APPENDIX B 

health effects occurring from a known length of exposure, locate the applicable exposure period 

within the LSE table and figure. 

(3)	 Health Effect The major categories of health effects included in LSE tables and figures are death, 

systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and 

LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are 

further defined in the “System” column of the LSE table (see key number 18). 

(4)	 Key to Figure Each key number in the LSE table links study information to one or more data 

points using the same key number in the corresponding LSE figure. In this example, the study 

represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 

(also see the 2 “18r” data points in Figure 2-l). 

(5)	 Species The test species, whether animal or human, are identified in this column. Section 2.5, 

“Relevance to Public Health,” covers the relevance of animal data to human toxicity and Section 

2.3, “Toxicokinetics,” contains any available information on comparative toxicokinetics. Although 

NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses 

to derive an MRL. 

(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 

regimen are provided in this column. This permits comparison of NOAELs and LOAELs from 

different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via 

inhalation for 6 hours per day, 5 days per week, for 3 weeks. For a more complete review of the 

dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., 

Nitschke et al. 1981. 

(7)	 System This column further defines the systemic effects. These systems include: respiratory, 

cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 

“Other” refers to any systemic effect (e.g., a decrease in body weight) not covered in these 

systems. In the example of key number 18, 1 systemic effect (respiratory) was investigated. 

(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which 

no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 

ppm for the respiratory system which was used to derive an intermediate exposure, inhalation 

MRL of 0.005 ppm (see footnote “b”). 

(9) LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 

that caused a harmful health effect. LOAELs have been classified into “Less Serious” and 

“Serious” effects. These distinctions help readers identify the levels of exposure at which adverse 

health effects first appear and the gradation of effects with increasing dose. A brief description of 

the specific end point used to quantify the adverse effect accompanies the LOAEL. The 

respiratory effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm. 

MRLs are not derived from Serious LOAELs. 

(10) Reference The complete reference citation is given in chapter 8 of the profile. 

(11) CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 

carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious 

effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 

doses not causing measurable cancer increases. 
HMX	 B-3 

APPENDIX B
 

(12) Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in 

the footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 was used to derive 

an MRL of 0.005 ppm. 

LEGEND 

See Figure 2-1 

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the 

reader quickly compare health effects according to exposure concentrations for particular exposure 

periods. 

(13)	 Exposure Period The same exposure periods appear as in the LSE table. In this example, health 

effects observed within the intermediate and chronic exposure periods are illustrated. 

(14)	 Health Effect These are the categories of health effects for which reliable quantitative data exists. 

The same health effects appear in the LSE table. 

(15)	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are 

graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 

scale “y” axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 

mg/kg/day. 

(16)	 NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate 

inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle 

symbol indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the 

entry in the LSE table. The dashed descending arrow indicates the extrapolation from the 

exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote “b” in 

the LSE table). 

(17)	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The 

diamond symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 

corresponds to the entry in the LSE table. 

(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 

upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are 

derived from the EPA’s Human Health Assessment Group’s upper-bound estimates of the slope of 

the cancer dose response curve at low dose levels (q1*). 

(19) Key to LSE Figure The Key explains the abbreviations and symbols used in the figure. 


HMX B-6 

APPENDIX B 

Chapter 2 (Section 2.5) 

Relevance to Public Health 

The Relevance to Public Health section provides a health effects summary based on evaluations of 

existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present 

interpretive, weight-of-evidence discussions for human health end points by addressing the following 

questions. 

1. What effects are known to occur in humans? 

2 . What effects observed in animals are likely to be of concern to humans? 

3. What exposure conditions are likely to be of concern to humans, especially around hazardous

 waste sites? 

The section covers end points in the same order they appear within the Discussion of Health Effects by 

Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human data 

are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). In 

vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 

considered in this section. If data are located in the scientific literature, a table of genotoxicity 

information is included. 

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 

existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 

potency or perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer end points (if 

derived) and the end points from which they were derived are indicated and discussed. 

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to 

public health are identified in the Data Needs section. 

Interpretation of Minimal Risk Levels 

Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 

inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). 

These MRLs are not meant to support regulatory action; but to acquaint health professionals with 

exposure levels at which adverse health effects are not expected to occur in humans. They should help 

physicians and public health officials determine the safety of a community living near a chemical 

emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs 

are based largely on toxicological studies in animals and on reports of human occupational exposure. 

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 

2.5, “Relevance to Public Health,” contains basic information known about the substance. Other 

sections such as 2.7, “Interactions with Other Substances,” and 2.8, “Populations that are Unusually 

Susceptible” provide important supplemental information. 

MRL users should also understand the MRL derivation methodology. MRLs are derived using a 

modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 

provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs). 

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 

represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
HMX B-7 

APPENDIX B 

cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is 

available for all potential systemic, neurological, and developmental effects. If this information and 

reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most 

sensitive species (when information from multiple species is available) with the highest NOAEL that 

does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverseeffect 

level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be 

employed. Additional uncertainty factors of 10 must be used both for human variability to protect 

sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) 

and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these 

individual uncertainty factors are multiplied together. The product is then divided into the inhalation 

concentration or oral dosage selected from the study. Uncertainty factors used in developing a 

substance-specific MRL are provided in the footnotes of the LSE Tables.